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Lung  squamous  cell  carcinoma  (LSCC)  comprises  ~30%  of  non-­‐‑small  cell  lung  
cancers,  and  currently  lacks  effective  targeted  therapies.  Previous  immunohistochemical  
and  microarray  studies  reported  overexpression  of  Hedgehog  (HH)-­‐‑GLI  signaling  
components  in  LSCC.  However,  they  addressed  neither  the  tumor  heterogeneity  nor  the  
requirement  for  HH-­‐‑GLI  signaling.  Here,  we  investigated  the  role  of  HH-­‐‑GLI  signaling  
in  LSCC,  and  studied  the  therapeutic  potential  of  HH-­‐‑GLI  pathway  suppression.    
Gene  expression  datasets  of  two  independent  LSCC  patient  cohorts  were  
analyzed  to  study  the  activation  of  HH-­‐‑GLI  signaling.  Four  human  LSCC  cell  lines  were  
examined  for  HH-­‐‑GLI  signaling  components.  Cell  proliferation  and  apoptosis  were  
assayed  in  these  cells  after  blocking  the  HH-­‐‑GLI  pathway  by  lentiviral-­‐‑shRNA  
knockdown  or  small  molecule  inhibitors.  Xenografts  in  immunodeficient  mice  were  
used  to  determine  the  in  vivo  efficacy  of  GLI  inhibitor  GANT61.    
In  both  patient  cohorts,  we  found  that  activation  of  HH-­‐‑GLI  signaling  was  
significantly  associated  with  the  classical  subtype  of  LSCC.  GLI2  expression  level  was  
significantly  higher  than  GLI1,  and  displayed  strong  positive  correlations  with  the  
prominent  markers  for  the  classical  subtype  (SOX2,  TP63  and  PIK3CA)  on  chromosome  
3q.  In  cell  lines,  genetic  knockdown  of  SMO  produced  minor  effects  on  cell  survival,  
while  GLI2  knockdown  significantly  reduced  proliferation  and  induced  extensive  
    
v  
apoptosis.  Consistently,  the  SMO  inhibitor  GDC-­‐‑0449  resulted  in  limited  cytotoxicity  in  
LSCC  cells,  whereas  the  GLI  inhibitor  GANT61  was  very  effective.  Importantly,  
GANT61  demonstrated  specific  in  vivo  anti-­‐‑tumor  activity  in  xenograft  models  of  GLI-­‐‑
positive  cell  lines.    
Taken  together,  we  report  SMO-­‐‑independent  regulation  of  GLI  in  LSCC,  and  
demonstrate  an  important  role  for  GLI2  in  LSCC.  Different  from  standard-­‐‑of-­‐‑care  
chemotherapy  or  small  molecule  inhibition  of  kinase  signaling  cascades,  we  present  a  
novel  and  potent  strategy  to  treat  a  subset  of  LSCC  patients  by  targeting  the  GLI  
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1. Background and Overview1  
1.1 Lung squamous cell carcinoma 
1.1.1 General 
Lung  cancer  is  the  leading  cause  of  cancer-­‐‑related  death  worldwide.  Non-­‐‑small  
cell  lung  cancer  (NSCLC)  comprises  ~80%  of  all  lung  cancer  cases,  which  includes  three  
major  histological  types:  squamous  cell  carcinoma  (20~30%),  adenocarcinoma  (~40%)  
and  large  cell  carcinoma  (~10%).  Squamous  cell  carcinoma  (SCC)  is  associated  most  
strongly  with  cigarette  smoking.  Archetypically,  SCC  commonly  occurs  in  the  main  
stem,  lobar,  and  segmental  bronchi  as  central  airway  tumors,  while  the  frequency  of  
peripheral  SCC  is  greatly  increasing  recently.  Clinically,  patients  with  central  SCC  
tumors  can  present  with  cough  shortness  of  breath,  and  fever  secondary  to  atelectasis  
and  postobstructive  pneumonia.  Hemoptysis  is  an  important  feature  that  can  be  related  
to  both  location  and  an  increased  proclivity  towards  cavitation.  Compared  with  lung  
adenocarcinoma,  SCC  tends  to  be  locally  aggressive  with  less  frequent  metastasis  to  
distant  organs  (1).  
                                                                                                              
1  The  main  part  of  this  dissertation  has  been  published  in  the  journal  Clinical  Cancer  Research  (Huang  et  al.,  
2014).  To  reproduce  the  contents,  including  the  figures,  from  the  published  article  in  this  dissertation  is  
retained  as  the  author’s  non-­‐‑exclusive  right  and  permitted  by  the  American  Association  for  Cancer  Research  
(AACR)  Publications  policy.  
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1.1.2 Pathologic Features 
Histologically,  well  differentiated  LSCCs  are  characterized  by  keratinization,  
intercellular  bridges  and  pearl  formation  (Figure  1).  Tumor  cells  are  usually  large  with  
abundant  dense  cytoplasm,  irregular  hyperchromatic  nuclei  and  small  nucleoli.  These  
features  can  be  present  only  focally  in  poorly  differentiated  LSCCs  (1).  
Immunohistochemical  (IHC)  staining  for  Tumor  Protein  p63  (TP63)  and  Thyroid  
Transcription  Factor  1  (NKX2-­‐‑1/  TTF-­‐‑1)  has  been  used  to  determined  histology  in  
challenging  specimens  in  order  to  guide  further  molecular  tests.  TP63  is  a  transcription  
factor  essential  for  stratified  squamous  epithelium  development.  TTF-­‐‑1  is  a  protein  that  
regulates  transcription  of  genes  specific  for  the  thyroid,  lung  and  diencephalon.  LSCC  
commonly  expresses  TP63,  and  is  negative  for  TTF-­‐‑1.  
1.1.3 Clinical treatments  
Management  of  NSCLCs  has  changed  dramatically  during  the  past  decade  due  
to  the  discovery  of  molecular  oncogenic  mechanisms.  Although  targeted  therapies  
resulted  from  these  discoveries  continue  to  improve  clinical  care,  the  benefit  to  patients  
has  largely  favored  those  with  lung  adenocarcinoma.  In  contrast,  progress  in  LSCC  
treatment  has  been  modest,  and  targeted  therapeutics  are  still  lacking.  Chemotherapy  
remains  the  first-­‐‑line  treatment  for  most  patients  with  stage  IV  NSCLC,  and  optimal  
regimens  are  now  guided  by  histology.  Platinum-­‐‑based  regimens  with  pemetrexed,  
bevacizumab  (a  monoclonal  antibody  against  VEGF),  or  both  are  reasonable  first-­‐‑line  
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options  for  patients  with  non-­‐‑squamous  NSCLC.  No  agents  are  currently  approved  
specifically  for  the  treatment  of  LSCC.  In  a  preplanned  subgroup  analysis  based  on  
histology,  the  combination  of  cisplatin  and  gemcitabine  was  associated  with  a  1.4-­‐‑month  
survival  advantage  compared  with  the  combination  of  cisplatin  and  pemetrexed  (10.8  
months  with  gemcitabine  versus  9.4  months  with  pemetrexed).  Therefore,  the  standard  
treatment  remains  a  platinum  doublet  with  a  drug  other  than  pemetrexed  (2).    
1.2 Molecular carcinogenesis of LSCC 
1.2.1 Oncogenic gene alterations 
In  contrast  to  adenocarcinoma,  druggable  molecular  drivers  have  not  been  
identified  in  LSCC,  and  the  current  targeted  agents  for  lung  adenocarcinoma  are  largely  
ineffective  for  treating  LSCC  patients.  Gradually,  oncogenic  alterations  have  been  
described  in  LSCC,  including  SOX2  amplification,  dysregulation  of  the  KEAP-­‐‑NFE2L2  
pathway,  aberrant  PI3K  pathway  activity,  FGFR1  amplification,  and  DDR2  mutation  (1).    
SOX2,  short  for  sex  determining  region  Y-­‐‑box2,  is  a  High  Mobility  Group  (HMG)  
transcription  factor,  essential  for  stem  cell  pluripotency.  Sox2  is  required  for  precise  
branching  morphogenesis  and  epithelial  cell  differentiation  during  lung  development  (3,  
4),  as  well  as  the  self-­‐‑renewal  ability  of  basal  cells  after  injury  (5).  Recently,  SOX2  is  
reported  to  be  an  amplified  lineage-­‐‑survival  oncogene  in  human  LSCC  (6,  7).  Sox2  is  also  
upregulated  in  squamous  cell  carcinomas  of  different  organ  sites  (6,  8).  SOX2  
knockdown  reduces  cell  proliferation  of  SOX2-­‐‑overexpressing  LSCC  cell  lines  in  vitro  
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(6).  Lung–specific  Sox2  overexpression  in  mouse  models  is  tumorigenic  (9).  These  
studies  collectively  demonstrate  a  critical  role  of  SOX2  in  LSCC.  
  
  
Figure  1:  Pathological  features  of  LSCC  
A.  Classic  morphological  features  of  LSCC:  keratinized  cells  forming  cellular  
pearls  (arrows)  and  intercellular  bridges  (inset).  B.  Cytoplasmic  keratinization  in  well  
differentiated  LSCC  (bright  red,  orange  and  blue).  C.  Examples  of  a  poorly  differentiated  
area  of  LSCC,  where  classic  morphological  differentiation  is  lacking.  D.  TP63  staining  in  
poorly  differentiated  LSCC.  (Adapted  from  Drilon  et  al.  (1))  
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The  KEAP-­‐‑NFE2L2  pathway  is  important  in  regulating  cellular  responses  to  
oxidative  and  xenobiotic  stress.  Under  stressful  condition,  modified  KEAP1  decreases  
the  degradation  of  NFE2L2,  which  is  the  transcriptional  activator  for  cytoprotective  
genes  in  elimination  of  reactive  oxygen  species,  xenobiotic  metabolism,  and  drug  
transport.  Mutations  in  the  coding  region  of  NFE2L2  occur  predominantly  in  LSCC  
patients  and  are  associated  with  a  history  of  smoking  (10,  11).  Cells  with  NFE2L2  
mutations  display  constitutive  induction  of  drug  efflux  pumps  and  cytoprotective  
enzymes,  and  NFE2L2  knockdown  abrogates  these  effects  (10).    
The  phosphatidylinositol  3-­‐‑kinase  (PI3K)  pathway  plays  a  central  role  in  cell  
survival,  metabolism,  motility  and  angiogenesis.  Several  studies  show  that  abnormal  
PI3K  signaling  is  more  common  in  LSCC  than  in  lung  adenocarcinoma.  Amplification  of  
PIK3CA,  the  gene  encoding  the  catalytic  subunit  of  PI3K,  is  prevalent  in  LSCC  (12-­‐‑14).  
PTEN  is  a  tumor  suppressor  gene  that  negatively  regulates  the  PI3K-­‐‑AKT-­‐‑mTOR  axis,  
and  loss  of  PTEN  function  that  results  in  increased  pathway  activity  has  been  reported  
in  LSCC  (15).      
The  Fibroblast  Growth  Factor  Receptor  (FGFR)  is  a  transmembrane  receptor  
tyrosine  kinase  that  participates  in  the  regulation  of  embryonic  development,  cell  
proliferation,  differentiation  and  angiogenesis.  The  FGFR  family  has  four  members  and  
binds  up  to  22  FGF  ligands.  Frequent  and  focal  FGFR1  amplifications  are  reported  in  
LSCC  specimen  (16,  17).  Cell  lines  endogenously  harboring  FGFR1  amplification  show  
  6  
growth  dependency  on  this  amplification,  suggesting  FGFR1  as  a  potential  therapeutic  
target  in  LSCC.  
The  Discoidin  Domain  Receptor  (DDR)  is  a  receptor  tyrosine  kinase  that  
regulates  cell  adhesion,  proliferation,  and  extracellular  remodeling  upon  binding  to  its  
endogenous  ligand,  collagen.  DDR2  mutation  presents  in  4%  of  LSCC.  Gain-­‐‑of-­‐‑function  
mutation  of  DDR2  can  be  inhibited  by  dasatinib,  a  multi-­‐‑kinase  inhibitors  against  both  
DDR1  and  DDR2  (18),  raising  the  treatment  possibility  for  molecularly  selected  patients  
with  LSCC.    
1.2.2 mRNA expression subtypes 
LSCC  has  broad  morphologic,  genetic  and  clinical  heterogeneity.  Currently,  no  
subclassification  adequately  addresses  this  variability  and  LSCCs  are  treated  as  a  single  
disease.  Recent  analysis  of  gene  expression  of  resected  tumors  has  classified  LSCC  into  
four  mRNA  expression  subtypes,  defined  as  classical  (36%),  primitive  (15%),  secretory  
(24%)  and  basal  (25%)  (19,  20).  The  four  subtypes  have  significantly  different  survival  
outcomes,  patient  populations,  and  biological  characteristics.  The  primitive  subtype  has  
the  worst  overall  survival  and  relapse-­‐‑free  survival  in  all  stages  of  LSCC,  whereas  the  
other  three  subtypes  have  similar  outcomes.  Genes  associated  with  cellular  proliferation,  
as  well  as  DNA  repair  and  RNA  processing,  are  overexpressed  in  the  primitive  subtype  
(19).  The  classical  subtype,  which  has  the  greatest  concentration  of  smokers  and  heaviest  
smokers,  exhibits  overexpression  of  genes  related  to  xenobiotic  metabolism,  which  
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detoxifies  foreign  chemicals.  The  classical  subtype  is  also  characterized  by  alterations  in  
KEAP1,  NFE2L2  and  PTEN,  as  well  as  the  greatest  overexpression  of  the  three  known  
oncogenes  on  chromosome  3q:  SOX2,  TP63  and  PIK3CA  (20).  Immune  response  related  
genes  and  lung  secretory  cell  markers  are  overexpressed  in  the  secretory  subtype.  The  
basal  subtype  shows  an  enrichment  of  genes  related  to  cell  adhesion  and  epidermal  
development  (19).  The  oncogenic  drivers  and  potential  cells  of  origin  of  tumors  within  
these  subtypes  are  likely  different.  Although  the  subtypes  may  help  to  stratify  patients  
for  more  precise  prognosis  and  targeted  therapies,  the  practical  application  of  these  
expression  subtypes  in  clinical  care  has  not  been  determined.  
1.3 Hedgehog-GLI signaling 
1.3.1 Canonical Hedgehog-GLI signaling 
As  illustrated  in  Figure  2,  canonical  Hedgehog  (HH)-­‐‑GLI  signaling  is  initiated  by  
the  binding  of  HH  ligands  (Sonic,  Indian  and  Desert  Hedgehog)  to  a  12-­‐‑transmembrane  
receptor  Patched  (PTCH).  The  binding  of  HH  to  PTCH  relieves  the  catalytic  inhibition  of  
Smoothened  (SMO),  a  7-­‐‑transmembrane  G-­‐‑protein  coupled  receptor  (GPCR)-­‐‑like  signal  
transducer.  SMO  de-­‐‑repression  triggers  a  series  of  intracellular  events,  resulting  in  the  
activation  of  downstream  target  genes  through  the  transcriptional  effectors  GLI1,  GLI2  
and  GLI3  (21).  The  GLI  effectors  are  regulated  by  complex  mechanisms  at  both  the  
transcriptional  and  post-­‐‑translational  levels.  They  have  activator  and  repressor  functions  
that  are  defined  only  partially  and  can  respond  to  combinatorial  and  cooperative  GLI  
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activity  (22).  GLI2  appears  to  be  the  primary  activator  of  HH  signaling  in  cancer,  with  
GLI1  as  a  transcriptional  target  of  GLI2  (23-­‐‑25).  GLI2  and  GLI1  also  induce  transcription  
of  overlapping  and  distinct  sets  of  downstream  target  genes  (26).  Several  components  of  
the  HH  pathway  (PTCH,  GLI1,  GLI2,  HHIP)  are  GLI  transcriptional  targets  that  induce  
positive  or  negative  feedbacks.  GLI  targets  mediate  various  cellular  responses,  notably  
enhanced  cell  proliferation  and  survival  by  upregulating  D-­‐‑type  cyclins  and  anti-­‐‑
apoptotic  proteins  (27-­‐‑29).  
  
  
Figure  2:  Ligand-­‐‑dependent  activation  of  canonical  HH-­‐‑GLI  signaling  
  (Adapted  from  di  Magliano  et  al.  (21))  
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1.3.2 Non-canonical Hedgehog-GLI signaling 
Constitutive  activation  of  HH-­‐‑GLI  signaling,  which  may  be  caused  by  ectopic  
expression  of  SHH  ligand,  loss-­‐‑of-­‐‑function  mutations  of  PTCH  or  SUFU,  constitutively  
active  SMO,  and  overexpression  of  GLI,  has  been  reported  to  be  tumorigenic.  In  
addition,  PI3K/AKT  and  RAS-­‐‑MEK  signals  have  been  described  as  non-­‐‑canonical  HH-­‐‑
GLI  activators  in  a  context-­‐‑dependent  manner.  Studies  show  that  PI3K-­‐‑depedent  Akt  
positively  regulates  Shh-­‐‑Gli  signaling  by  controlling  Protein  Kinase  A  (PKA)-­‐‑mediated  
Gli2  inactivation  (30).  While  active  SHH-­‐‑GLI  signaling  in  the  matrix  of  human  hair  
follicles  is  required  for  proliferation  of  melanocytes,  oncogenic  Ras-­‐‑induced  melanomas  
in  transgenic  mice  express  Gli1  and  require  Gli  signaling  both  in  vitro  and  in  vivo  for  
growth  and  metastasis.  Endogenous  Ras-­‐‑Mek  and  Akt  signaling  also  regulate  the  
nuclear  localization  and  transcriptional  activity  of  GLI1  in  melanoma  (31).  In  transgenic  
mouse  model  of  pancreatic  ductal  adenocarcinoma,  Gli  transcription  is  decoupled  from  
Shh-­‐‑Ptch-­‐‑Smo  axis  and  is  regulated  by  TGF-­‐‑β  and  Kras.  Gli  activity  is  required  both  for  
survival  and  the  Kras-­‐‑mediated  transformed  phenotypes  of  cultured  pancreatic  cancer  
cells  (32).  HH-­‐‑GLI  signaling  also  cross-­‐‑talks  with  other  oncogenic  pathways,  forming  a  
complex  cellular  network.    
1.3.3 Hedgehog-GLI signaling in lung development 
HH-­‐‑GLI  signaling  plays  a  critical  role  in  lung  morphogenesis.  Shh  ligand  is  
specifically  expressed  in  the  budding  airway  epithelium  during  lung  embryogenesis,  
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which  is  required  for  branching  morphogenesis  and  epithelial-­‐‑mesenchymal  interaction  
(33).  Shh-­‐‑deficient  mice  exhibit  hypoplastic  lungs  and  severe  branching  defects,  whereas  
overexpression  of  Shh  results  in  increased  cell  proliferation  to  a  lung  containing  
abundant  mesenchyme  and  not  functional  alveoli  (34,  35).  Mutations  in  the  Gli  genes  
give  rise  to  various  lung  and  foregut  defects.  While  Gli1  is  dispensable  for  lung  
development  in  the  presence  of  other  Gli  genes  (36),  Gli2−/−  mutant  lung  exhibits  lobe  
hypoplasia,  narrowing  of  the  trachea  and  esophagus  (37).  Compound  mutants  lacking  
both  Gli2  and  Gli3  are  severely  defective  in  upper  foregut  structures  lacking  lung,  
trachea,  and  esophagus  (37).  While  these  findings  point  to  the  importance  of  HH-­‐‑GLI  
signaling  in  lung  development,  the  functional  involvement  of  this  pathway  in  adult  lung  
and  lung  cancer  is  less  understood.  
1.3.4 Hedgehog-GLI signaling in airway repair and small cell lung 
cancer 
Dysregulation  of  the  HH-­‐‑GLI  pathway  has  been  implicated  in  carcinogenesis,  
maintenance  of  tumor  progenitor  cells  and  tumor-­‐‑stromal  interaction  in  a  variety  of  
cancers  (38).  Despite  its  importance  during  lung  morphogenesis,  HH-­‐‑GLI  signaling  
remains  largely  quiescent  in  adult  lung  homeostasis.  Adult  lung  airway  epithelium  
rarely  proliferates  unless  injured.  In  a  mouse  model  of  acute  airway  repair,  when  Clara  
cells  in  the  distal  conducting  airways  are  depleted  by  systemic  naphthalene  
administration,  widespread  activation  of  the  Shh-­‐‑Gli  pathway  is  observed  in  the  
increased  neuroendocrine  cells  in  the  regenerating  airway  epithelium  (39).  Small  cell  
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lung  cancer  is  (SCLC)  an  aggressive,  highly  lethal  malignance  with  primitive  
neuroendocrine  features.  Analysis  of  SCLC  tissues  reveals  expression  of  SHH  and  GLI1.  
SCLC  xenografts  in  nude  mice  demonstrate  SHH-­‐‑expressing  cells  adjacent  to  GLI1-­‐‑
expressing  cells,  and  suppression  of  SHH-­‐‑GLI  signaling  by  SMO  antagonist,  
cyclopamine,  inhibits  growth  of  SCLC  xenografts  in  nude  mice  (39).  In  a  transgenic  
mouse  model  in  which  deletion  of  Rb1  and  p53  in  adult  lung  epithelium  induces  SCLC,  
Hh-­‐‑Gli  signaling  is  found  to  be  activated  in  SCLC  cells  independent  of  lung  
microenvironment.  Constitutively  active  SMO  enhances  the  survival  and  clonogenicity  
of  human  SCLC  in  vitro.  While  constitutive  activation  of  SMO  promotes  the  initiation  
and  progression  of  mouse  SCLC  in  vivo,  genetic  deletion  of  SMO  from  Rb1  and  p53  dual  
mutant  lung  epithelial  cells  strongly  suppresses  SCLC  initiation  and  progression  (40).  
Moreover,  pharmacological  blockage  of  HH-­‐‑GLI  signaling  with  SMO  inhibitor  
suppresses  both  mouse  and  human  SCLC  growth,  most  notably  following  
chemotherapy  (40).  Taken  together,  these  studies  demonstrate  a  crucial  role  of  HH-­‐‑GLI  
signaling  in  the  development  and  maintenance  of  SCLC,  and  suggest  HH-­‐‑GLI  inhibition  
as  a  therapeutic  strategy  to  treat  patients  with  SCLC.  
1.3.5 Hedgehog-GLI signaling in LSCC 
Although  the  involvement  of  HH-­‐‑GLI  signaling  in  small-­‐‑cell  lung  cancer  is  well  
established,  the  role  of  this  pathway  in  non-­‐‑small  cell  lung  cancer  remains  poorly  
understood.  However,  multiple  lines  of  evidence  point  to  the  potential  importance  of  
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HH-­‐‑GLI  signaling  in  LSCC.  As  shown  in  Figure  3,  immunohistochemical  (IHC)  studies  
in  patient  specimens  report  the  overexpression  of  HH  signaling  components  (SHH,  
PTCH,  SMO,  GLI1  and  GLI2)  in  LSCC,  but  absent  from  the  adjacent  non-­‐‑neoplastic  lung  
parenchyma  (41,  42).  High  activation  of  the  HH-­‐‑GLI  pathway  defined  by  the  intensity  of  
IHC  staining  is  observed  in  approximately  27%  of  LSCC.  Analysis  of  three  published  
microarray  datasets  identifies  hyperactive  HH  signaling  in  LSCC  in  comparison  to  
normal  lung  tissues  (43).  GLI-­‐‑mediated  HH  signaling  has  been  implicated  in  squamous  
cancer  of  other  organs,  including  cancer  of  the  oral  mucosa  and  esophagus  (44-­‐‑46).  
Despite  these  studies,  very  little  is  known  regarding  the  specific  role  of  HH  signaling  in  
regulation  of  cellular  survival  and  proliferation  in  LSCC.  
  
  
Figure  3:  IHC  staining  of  HH  signaling  components  in  LSCC  
Upper  panel:  negative  staining  of  HH  components  in  alveolar  epithelium  and  
interstitium  of  adjacent  non-­‐‑neoplastic  lung  parenchyma.  Bottom  panel:  Increased  
staining  of  indicated  HH  components  in  LSCC.  (Adapted  from  Gialmanidis  et  al.  (41))  
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1.3.6 Inhibitors of Hedgehog-GLI signaling 
Targeted  inhibitors  of  the  HH  pathway  have  become  available  recently.  Because  
of  its  accessibility  on  the  membrane  and  its  importance  in  regulation  of  the  pathway,  
SMO  has  been  the  primary  focus  in  the  development  of  small  molecule  inhibitors  of  the  
HH  pathway.  Cyclopamine,  a  natural  alkaloid  derivative,  represents  the  first  member  of  
small  chemical  compounds  that  specifically  inhibits  SMO  by  binding  to  its  heptahelical  
bundle.  However,  the  difficulty  to  synthesize  cyclopamine  in  large  quantities  makes  it  
not  applicable  as  a  therapeutic  agent.  GDC-­‐‑0449  (vismodegib;  Genentech)  is  an  orally  
administered  agent  that  selectively  suppresses  SMO  activity  and  subsequent  
downstream  signaling.  It  is  the  first  SMO  inhibitor  to  progress  to  clinical  trials  and  has  
recently  been  approved  for  use  as  a  first-­‐‑line  treatment  in  advanced  unresectable  basal  
cell  carcinoma.  Although  GDC-­‐‑0449  has  produced  promising  antitumor  responses  in  
patients  with  advanced  basal  cell  carcinoma  and  medulloblastoma  (47,  48),  resistance  to  
GDC-­‐‑0449  has  been  reported  in  a  patient  with  metastatic  medulloblastoma  who  was  
initially  highly  responsive  to  GDC-­‐‑0449  (49,  50).  Gene  sequencing  of  a  recurrent,  drug-­‐‑
resistant  tumor  from  this  patient  has  identified  a  SMO  missense  mutation,  D473H,  
which  decreased  the  binding  affinity  of  GDC-­‐‑0449  by  100-­‐‑fold.  Other  mutations  of  
human  or  murine  SMO  that  render  resistance  to  GDC-­‐‑0449  have  also  been  reported.  In  
addition,  other  putative  mechanisms  of  SMO-­‐‑inhibitor  resistance  have  also  been  
identified,  including  GLI2  and  Cyclin  D1  (CCND1)  amplification,  and  activation  of  the  
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PI3K-­‐‑AKT  signaling  pathway  (50).  The  resistance  to  SMO  inhibitors  highlights  the  
therapeutic  need  to  target  downstream  effectors  to  maintain  robust  on-­‐‑target  responses.    
In  a  cell-­‐‑based  screen  of  GLI-­‐‑mediated  transcription,  the  small  molecule  GANT61  
was  identified  as  a  specific  inhibitor  of  GLI1  and  GLI2  (51).  The  IC50  of  GANT61  in  
suppressing  the  Gli-­‐‑luciferase  reporter  activity  in  NIH  3T3  cells  is  approximately  5  
µμmol/L.  GANT61  functions  in  the  nucleus  to  suppress  the  DNA  binding  capacity  of  
GLIs  and  inhibits  both  GLI1-­‐‑  and  GLI2-­‐‑  mediated  transcription.  It  has  no  influence  on  
major  but  unrelated  signaling  pathways,  including  TNF  signaling/  NFκB  activation,  
glucocorticoid  receptor  gene  transactivation,  and  the  RAS-­‐‑RAF-­‐‑MEK-­‐‑MAPK  cascade.  
General  and  common  cellular  events,  such  as  correct  protein  folding,  nuclear  transport,  
or  basal  transcriptional  machinery  assembly  are  not  disturbed  by  GANT61.  Moreover,  
GANT61  is  inactive  in  several  other  screens  for  inhibitors  of  HGF/  Met,  C/EBPα  or  HIF-­‐‑1  
(51).  These  studies  collectively  demonstrate  a  high  selectivity  of  GANT61.  GANT61  
reduces  proliferation  and  induces  apoptosis  in  a  GLI-­‐‑specific  fashion  in  prostate  cancer  
(51),  colon  carcinoma  (52,  53),  oral  squamous  cell  carcinoma  (45),  pancreatic  cancer  (54),  
neuroblastoma  (55),  and  chronic  lymphocytic  leukemia  (56).  Figure  4  shows  the  
chemical  structures  of  cyclopamine,  GDC-­‐‑0449  and  GANT61.  
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Figure  4:  Chemical  structures  of  HH  inhibitors  
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2. Activation of HH-GLI signaling is associated with the 
classical subtype of human LSCC. 
2.1 Materials and Methods  
2.1.1 RNAseq and microarray analysis of patient specimens 
In  collaboration  with  Dr.  Vonn  Walter  and  Dr.  Neil  Hayes  at  the  University  of  
North  Carolina,  we  analyzed  two  independent  patient  cohorts:  (1)  RNA-­‐‑seq  data  of  178  
tumor  samples  from  The  Cancer  Genome  Atlas  LSCC  study  (TCGA  cohort)  (20),  and  (2)  
microarray  data  of  56  LSCC  samples  collected  at  the  University  of  North  Carolina  (UNC  
cohort)  (19).  RSEM  values  (57)  for  the  (20)  were  converted  to  gene  expression  
measurements  by  replacing  all  values  equal  to  zero  with  the  smallest  non-­‐‑zero  value,  
taking  a  log2  transformation,  and  median  centering  by  gene.  Heatmaps  of  the  gene  
expression  values  from  (20)  and  (19)  were  produced  with  R  2.15.1  (58)  and  the  gplots  
package.  Hypotheses  were  subsequently  tested:  One-­‐‑sided  Wilcoxon  Rank  Sum  tests  
were  used  to  test  the  null  hypothesis  that  the  mean  expression  levels  of  PTCH1,  GLI1,  
GLI2,  GLI3,  and  SUFU  are  the  same  in  the  classical  subtype  as  all  other  subtypes  
combined.    For  PTCH1,  GLI1,  and  GLI2,  the  alternative  hypothesis  was  that  the  
expression  levels  are  higher  in  the  classical  subtype,  whereas  for  GLI3  and  SUFU  the  
alternative  hypothesis  was  that  the  expression  levels  are  lower  in  the  classical  subtype.  
A  Bonferroni  adjustment  was  applied  to  correct  for  multiple  comparisons.  
  Two-­‐‑sided  Wilcoxon  Rank  Sum  tests  were  used  to  test  the  null  hypothesis  that  
GLI1  and  GLI2  expression  values  were  equal  in  the  TCGA  and  UNC  cohorts.  Spearman  
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correlation  coefficients  were  computed  based  on  the  uncentered  expression  values  of  
GLI1,  GLI2,  TP63,  PIK3CA,  and  SOX2  in  both  the  TCGA  and  UNC  cohorts.    The  resulting  
unadjusted  p  values  were  used  to  assess  the  significance  of  these  associations  (Table  2).    
2.2 Results 
2.2.1 Activation of HH-GLI signaling is associated with the classical 
subtype in both TCGA and UNC cohorts. 
In  collaboration  with  Dr.  Vonn  Walter  and  Dr.  Neil  Hayes,  we  queried  the  RNA  
expression  data  of  178  patient  samples  from  the  Cancer  Genome  Atlas  (TCGA)  LSCC  
study  to  ascertain  whether  HH  signaling  is  upregulated  in  a  particular  subset  of  LSCC  
patients.  As  Figure  5  demonstrates,  the  expression  of  HH  target  genes  (PTCH1,  GLI1,  
GLI2)  was  significantly  higher,  while  expression  of  negative  regulators  (GLI3,  SUFU)  
was  substantially  lower  in  the  classical  subtype  in  comparison  to  the  other  subtypes.  
One-­‐‑sided  Wilcoxon  Rank  Sum  Test  confirmed  these  observations  (Table  1)  even  after  
applying  a  Bonferroni  adjustment  for  multiple  comparisons.  Similar  expression  patterns  
were  seen  in  an  independent  cohort  of  56  LSCC  samples  collected  at  the  University  of  





Figure  5:  HH  activation  pattern  in  the  TCGA  cohort  
Heatmap  of  HH  signaling  components  in  the  TCGA  cohort.  Tumor  samples  are  
displayed  as  columns,  grouped  by  gene  expression  subtypes.  Selected  HH  genes  are  
rows.  Displayed  genes  of  HH  pathway  except  SHH,  showed  highly  significant  
association  with  gene  expression  subtype  (p<0.001)  (Table  1).  
  
Table  1:  Results  of  hypothesis  tests  used  to  compare  expression  values  of  HH  
genes  in  LSCC  subtypes  of  the  TCGA  cohort  
Gene   Alternative  Hypothesis   Unadjusted  p-­‐‑value   Adjusted  p-­‐‑value  
PTCH1   Greater  in  classical   1.81e-­‐‑7   9.07e-­‐‑7  
GLI1   Greater  in  classical   7.58e-­‐‑8   3.79e-­‐‑7  
GLI2   Greater  in  classical   4.99e-­‐‑16   2.49e-­‐‑15  
GLI3   Less  in  classical   1.20e-­‐‑7   5.98e-­‐‑7  




Figure  6:  HH  activation  pattern  in  the  UNC  cohort  
Heatmap  of  HH  signaling  components  in  the  UNC  cohort.  Tumor  samples  are  
displayed  as  columns,  grouped  by  gene  expression  subtypes.  Selected  HH  genes  are  
rows.  
  
2.2.2 GLI2 mRNA level is significantly higher than GLI1. 
As  shown  in  Figure  7,  GLI2  mRNA  level  was  significantly  higher  than  GLI1  in  
both  TCGA  cohort  (p=4.2×10-­‐‑5)  and  UNC  cohort  (p=0.016).  Samples  with  high  GLI2  
expression  were  mainly  found  in  the  classical  subtype  although  occasionally  in  other  
subtypes  (Figure  8).  We  defined  the  75th  percentile  of  all  GLI2  expression  values  in  a  
given  cohort  as  the  threshold  for  high  GLI2.  In  the  TCGA  cohort,  55%  of  all  classical  
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subtype  samples  exhibit  high  GLI2  expression.  Only  9  of  45  samples  with  high  level  of  
GLI2  lie  outside  the  classical  subtype.  In  the  UNC  cohort,  52%  of  all  samples  in  the  
classical  subtype  exhibit  high  GLI2  expression.  Only  3  of  14  samples  with  high  level  of  
GLI2  lie  outside  the  classical  subtype.  These  samples  with  high  GLI2  expression  
represent  tumors  with  hyperactive  HH  signaling.    
  
                 
Figure  7:  Comparison  of  mRNA  levels  of  GLI1  and  GLI2    
Left:  TCGA  cohort.  Right:  UNC  cohort.  Gene  expression  values  of  individual  
patients  are  colored  according  to  the  subtypes.  
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Figure  8:  Distribution  of  high  GLI2  samples  in  patient  cohorts  
Left:  TCGA  cohort;  Right:  UNC  cohort.  Gene  expression  values  are  plotted  
according  to  subtypes,  and  the  75th  percentile  of  all  GLI2  expression  is  shown  as  a  
horizontal  red  line.  
  
2.2.3 GLI2 is positively associated with the classical subtype 
markers. 
In  both  cohorts,  we  observed  strong  positive  correlations  between  GLI2  and  the  
prominent  markers  for  the  classical  subtype  on  chromosome  3q:  SOX2  (Figure  9),  TP63  
(Figure  10)  and  PIK3CA  (Figure  11).  However,  GLI1  was  only  associated  with  classical  
chr3q  genes  in  the  TCGA  cohort  (Figure  12),  suggesting  that  GLI2  is  highly  likely  to  be  
the  major  signaling  transducer  in  LSCC.  Spearman  correlation  coefficients  between  
GLI2/  GLI1  and  the  classical  subtype  markers  with  corresponding  p  values  were  
summarized  in  Table  2.    
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Figure  9:  Scatterplots  of  expression  measurements  between  GLI2  and  SOX2  
Left:  TCGA  cohort.  Right:  UNC  cohort.    
         
Figure  10:  Scatterplots  of  expression  measurements  between  GLI2  and  TP63  
Left:  TCGA  cohort.  Right:  UNC  cohort.    
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Figure  11:  Scatterplots  of  expression  measurements  between  GLI2  and  PIK3CA  
Left:  TCGA  cohort.  Right:  UNC  cohort.    
  
Table  2:  Spearman  correlation  coefficients  and  p  values  between  GLI2/  GLI1  
and  the  classical  subtype  markers  











GLI2   SOX2   0.48   <4.6×10-­‐‑12   0.46   3.7×10-­‐‑4  
GLI2   TP63   0.56   <2.2×10-­‐‑16   0.47   2.6×10-­‐‑4  
GLI2   PIK3CA   0.45   2.6×10-­‐‑10   0.27   0.046  
GLI1   SOX2   0.41   1.9×10-­‐‑8   Not  significant  
GLI1   TP63   0.33   8.2×10-­‐‑6   Not  significant  






Figure  12:  Scatterplots  of  expression  measurements  of  GLI1  and  classical  
subtype  markers  in  the  TCGA  cohort  
GLI1  is  only  correlated  with  SOX2  (upper  left),  TP63  (upper  right),  and  PIK3CA  





LSCC  has  long  been  treated  as  a  single  disease  due  to  the  limited  knowledge  of  
the  oncogenic  drivers  and  tumor  heterogeneity.  The  recent  discovery  of  mRNA  
expression  signatures  has  classified  LSCC  into  four  distinct  subtypes  with  different  
biological  features  and  survival  outcomes.  However,  the  clinical  application  of  this  
molecular  classification  has  not  been  evaluated.  Previous  IHC  studies  in  patient  
specimens  have  reported  overexpression  of  HH-­‐‑GLI  signaling  molecules  in  a  portion  of  
LSCC  samples,  but  failed  to  define  this  patient  subset  on  a  molecular  basis.  In  our  
studies,  we  confirm  the  activation  of  HH-­‐‑GLI  pathway  in  a  subset  of  LSCC  patients.  
Notably,  hyperactive  HH-­‐‑GLI  signaling  is  associated  with  the  classical  subtype  (≈36%  of  
LSCC).  GLI2  mRNA  level  is  significantly  higher  than  GLI1,  which  suggests  that  GLI2  is  
the  major  signal  transducer  in  LSCC.  Due  to  the  importance  of  GLI2  in  HH  signaling  
mediation,  we  consider  high  GLI2  expression  as  the  criteria  of  defining  tumors  with  
hyperactive  HH  pathway.  When  taking  the  75th  percentile  of  all  GLI2  expression  values  
in  a  given  cohort  as  the  threshold  for  high  GLI2,  25%  of  total  LSCC  samples  exhibit  high  
expression  of  GLI2.  This  percentage  is  consistent  with  previous  report  in  IHC  studies,  
which  show  high  activation  of  HH  signaling  in  27%  of  all  LSCC  specimens.  
Approximately  55%  of  the  classical  subtype  samples  display  high  expression  of  GLI2,  
while  samples  with  high  level  of  GLI2  are  occasionally  found  in  other  subtypes.  We  also  
observe  strong  positive  correlations  between  GLI2  and  the  classical  subtype  markers  
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(SOX2,  TP63  and  PIK3CA).  These  findings  revealed  aberrant  activation  of  HH  signaling  
in  the  classical  subtype,  featuring  a  consistently  high  expression  of  GLI2  and  indicating  a  
potentially  critical  role  of  GLI2  in  the  classical  subtype.  
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3. HH-GLI signaling components are expressed in 
human LSCC cell lines. 
3.1 Materials and Methods 
3.1.1 Cell culture and reagents 
NCI-­‐‑H520,  NCI-­‐‑H2170,  NCI-­‐‑H226  and  SK-­‐‑MES-­‐‑1  cells  were  obtained  from  
ATCC.  Cell  lines  were  routinely  verified  by  morphology  and  growth  characteristics,  and  
verified  biannually  to  be  mycoplasma-­‐‑free.  NCI-­‐‑H520,  NCI-­‐‑H2170  and  NCI-­‐‑H226  cells  
were  maintained  in  the  RPMI  1640  medium  containing  10%  fetal  bovine  serum  (FBS).  
SK-­‐‑MES-­‐‑1  cells  were  maintained  in  MEM  medium  containing  10%  FBS,  0.1  mM  non-­‐‑
essential  amino  acids,  1.0  mM  sodium  pyruvate.  
3.1.2 RNA isolation and Real-time PCR 
Total  RNA  was  isolated  using  the  Qiagen  RNeasy  Mini  Kit,  treated  with  DNase  I  
(Invitrogen)  and  converted  to  cDNA  using  iScript  cDNA  Synthesis  Kit  (BIO-­‐‑RAD).  Real-­‐‑
time  PCR  was  performed  using  TaqMan  Gene  Expression  Master  Mix  on  an  Eppendorf  
Mastercycler,  and  raw  data  were  analyzed  by  Realplex  software.  TaqMan  probes  for  
SHH,  PTCH1,  SMO,  GLI1,  GLI2,  and  GAPDH  were  purchased  from  Applied  Biosystems.    
3.1.3 Western analysis 
Total  cellular  lysates  were  prepared  by  using  RIPA  buffer  (Sigma)  with  addition  
of  protease  inhibitor  cocktail  (Sigma)  and  PhosSTOP  (Roche).  Protein  concentrations  
were  determined  by  Micro  BCA  Protein  Assay  Kit  (Thermo  Scientific).  Proteins  were  
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separated  on  the  NuPAGE  4-­‐‑12%  Bis-­‐‑Tris  Gel  (Life  Technologies)  and  transferred  using  
Invitrolon  PVDF  Filter  Paper  Sandwich.  Membranes  were  blocked  with  5%  nonfat  dry  
milk  in  Tris-­‐‑buffered  saline  with  0.1%  Tween  20  (0.1%  TBST)  for  1  hour  in  room  
temperature,  then  incubated  with  primary  antibody  overnight  at  4°C.  Membranes  were  
subsequently  washed  with  0.1%TBST  and  incubated  with  the  secondary  antibody  for  1  
hour  at  room  temperature.  Western  Lightning-­‐‑  ECL  (PerkinElmer)  was  used  to  develop  
the  membranes.  Antibodies:  SHH,  PTCH,  SMO  (Santa  Cruz);  GLI1  (Novus  Biologicals);  
GLI2,  GAPDH  (Abcam).  
3.1.4 Subtype prediction and validation in LSCC cell lines 
Gene  expression  data  from  20  LSCC  cell  lines  was  obtained  from  the  Cancer  Cell  
Line  Encyclopedia  (CCLE)  (59).  After  median  centering  the  expression  values  by  gene,  
the  centroid  classifier  from  (19)  was  used  to  predict  expression  subtypes  for  each  line  by  
finding  the  nearest  centroid  using  a  distance  metric  equal  to  one  minus  the  Pearson  
correlation  coefficient.    Gene  expression  heatmaps  were  then  produced  using  R2.15.1  
(58)  and  the  gplots  package.  
3.2 Results 
3.2.1 HH-GLI signaling components are present in human LSCC cell 
lines. 
The  difficulty  of  growing  human  LSCC  cells  in  vitro  limits  available  primary  
cancer  cells  to  test.  Therefore,  we  chose  the  four  most  widely  used  human  LSCC  cell  
lines  to  analyze  active  HH  signaling:  NCI-­‐‑H520  and  NCI-­‐‑H2170,  derived  from  primary  
  29  
tumors;  and  NCI-­‐‑H226  and  SK-­‐‑MES-­‐‑1,  derived  from  metastatic  pleural  effusions.  By  
real-­‐‑time  PCR  (Figure  13A)  and  Western  blots  (Figure  13B),  high  levels  of  SHH  were  
detected  only  in  NCI-­‐‑H520,  whereas  PTCH1  and  SMO  were  expressed  universally  
across  all  four  lines.  Neither  GLI1  nor  GLI2  was  detected  in  NCI-­‐‑H2170.  In  the  
remaining  three  lines,  GLI1  was  expressed  at  a  low  level,  whereas  high  levels  of  GLI2  
were  consistently  detected  at  both  the  mRNA  and  protein  level.  
3.2.2 NCI-H520 and NCI-H2170 represent classical LSCC, while NCI-
H226 and SK-MES-1 represent secretory LSCC. 
In  order  to  ascertain  whether  these  cell  lines  represent  different  human  primary  
LSCC  subtypes  by  mRNA  expression,  gene  expression  profiles  from  CCLE  (59)  were 
analyzed. NCI-H520 and NCI-H2170 were predicted to be classical subtype, and NCI-H226 and 
SK-MES-1 as secretory subtype. Gene expression of the subtypes between the cell lines and 
patient tumors is consistent over the validation gene set (Figure 14). 
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Figure  13:  HH  signaling  components  are  expressed  in  LSCC  cell  lines  
A.  Real-­‐‑time  PCR  for  indicated  genes,  with  GAPDH  as  the  quantitative  control.    
B.  Western  Blot  for  the  SHH-­‐‑GLI  pathway  components,  with  GAPDH  as  the  
loading  control.  Classical  subtype:  NCI-­‐‑H520  and  NCI-­‐‑H2170;  Secretory  subtype:  NCI-­‐‑




Figure  14:  Heatmap  of  subtype  validation  gene  expression  for  LSCC  cell  lines  
Classical  subtype:  NCI-­‐‑H520  and  NCI-­‐‑H2170;  Secretory  subtype:  NCI-­‐‑H226  and  
SK-­‐‑MES-­‐‑1.  Subtype  prediction  was  based  on  the  expression  subtype  classifier  genes  as  
described  by  Wilkerson  et  al.  (19).  Expression  patterns  for  cell  lines  predicted  to  be  in  the  
classical  or  secretory  subtypes  are  similar  to  those  seen  in  Figure  2  of  Wilkerson  et  al.  
  
3.3 Summary 
We  observe  the  expression  of  HH-­‐‑GLI  signaling  molecules  in  the  four  most  
widely  used  human  LSCC  cell  lines,  which  provide  valuable  resources  for  further  study.  
These  cell  lines  represent  the  classical  and  secretory  subtypes  respectively  as  observed  in  
primary  human  LSCC.  When  the  classical  subtype  contains  the  highest  percentage  of  
high  GLI2  samples,  a  few  samples  show  low  level  of  GLI2  comparable  to  the  majority  of  
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the  other  three  subtypes.  Although  both  predicted  as  the  classical  subtype,  NCI-­‐‑H520  
and  NCI-­‐‑H2170  represent  two  different  levels  of  HH  activation.  NCI-­‐‑H226  and  SK-­‐‑MES-­‐‑
1  may  represent  individual  samples  in  the  secretory  subtype  that  display  high  
expression  of  GLI2.  
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4. SMO plays a minor role in HH-GLI signaling mediation 
and survival in LSCC cell lines.  
4.1 Materials and Methods 
4.1.1 Lentiviral production and transduction 
Lentiviral  shRNA  clones  (Sigma  Mission  RNAi)  targeting  SMO  and  the  non-­‐‑
targeting  control  (SHC002)  were  purchased  from  Sigma-­‐‑Aldrich.  293T  cells  were  plated  
in  10-­‐‑cm  plates  24  hours  prior  to  transfection  in  DMEM  medium  containing  10%  fetal  
bovine  serum  (FBS)  without  antibiotics.  5  µμg  shRNA  plasmid,  4  µμg  psPAX2  and  1  µμg  
pCI-­‐‑VSVG  packaging  vectors  (Addgene)  were  co-­‐‑transfected  into  293T  cells  using  
Lipofectamine  2000  Reagent  (Invitrogen).  Viral  supernatants  were  collected,  centrifuged  
and  filtered  with  0.45  µμm  PES  Sterile  Syringe  Filter.  Target  cells  were  plated  and  
incubated  at  37°C,  5%  CO2  overnight,  and  changed  to  medium  containing  lentivirus  and  
8  µμg/mL  polybrene.  Control  plates  were  incubated  with  medium  containing  8  µμg/mL  
polybrene.  Cells  were  changed  to  fresh  culture  medium  24  hours  after  infection.  
Puromycin  selection  (5  µμg/ml)  was  started  48  hours  post  infection  and  continued  for  4~5  
days  until  no  viable  cells  were  observed  in  control  plates.  Once  decreased  expression  of  
the  targeted  gene  was  confirmed,  cells  were  used  for  subsequent  experiments.  Stable  
expression  of  non-­‐‑targeting  control  or  SMO  shRNAs  was  ensured  by  culturing  cells  in  
the  presence  of  puromycin.  Sequences  of  shRNA  constructs  are  provided  as  below:  
SMO  sh1  (5’-­‐‑  CCGGCCTGATGGACACAGAACTCATCTCGAGATGAGTTCTG  
TGTCCATCAGGTTTTT-­‐‑3’)  
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SMO  sh2  (5’-­‐‑  CCGGCATCTTTGTCATCGTGTACTACTCGAGTAGTACACGA  
TGACAAAGATGTTTTT-­‐‑3’)  
SMO  sh3  (5’-­‐‑  CCGGGTGGAGAAGATCAACCTGTTTCTCGAGAAACAGGTTG  
ATCTTCTCCACTTTTT-­‐‑3’)  
4.1.2 RNA isolation and Real-time PCR 
Total  RNA  was  isolated  using  the  Qiagen  RNeasy  Mini  Kit,  treated  with  DNase  I  
(Invitrogen)  and  converted  to  cDNA  using  iScript  cDNA  Synthesis  Kit  (BIO-­‐‑RAD).  Real-­‐‑
time  PCR  was  performed  using  TaqMan  Gene  Expression  Master  Mix  on  an  Eppendorf  
Mastercycler,  and  raw  data  were  analyzed  by  Realplex  software.  TaqMan  probes  for  
PTCH1,  SMO,  GLI2,  HHIP1,  and  GAPDH  were  purchased  from  Applied  Biosystems.    
4.1.3 Assessment of cell viability and caspase 3/7 activity 
In  GDC-­‐‑0449  treatment,  cells  were  seeded  in  96-­‐‑well  clear-­‐‑bottom  white  plates  
(Corning  Costar)  at  a  density  of  10,000  cells  per  well  and  incubated  with  complete  
medium  overnight  at  37°C,  5%  CO2.  The  following  day,  cells  were  changed  into  0.5%  
FBS-­‐‑containing  medium  with  either  DMSO  control  or  GDC-­‐‑0449  (Chemietek)  at  
designated  concentrations  (0.1%  final  DMSO  concentration)  as  triplicates  and  treated  for  
96  hours.  At  the  end  of  treatment,  cell  viability  and  caspase  3/7  activity  were  determined  
by  using  ApoLive-­‐‑Glo  Multiplex  Assay  (Promega)  according  to  the  manufacturer’s  
instructions.  Briefly,  viability  reagent  was  added  into  all  wells  and  gently  mixed.  After  
1.5-­‐‑hour  incubation  at  37°C,  fluorescence  was  measured  at  the  wavelength  set  355EX/  
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520EM  by  a  FLUOstar  Omega  Microplate  reader.  Later,  Caspase-­‐‑Glo®  3/7  Reagent  was  
added  to  all  wells  and  gently  mixed.  Luminescence  was  measured  after  1-­‐‑hour  
incubation  at  room  temperature.  The  reading  of  blank  control  was  subtracted  from  
readings  of  other  wells  as  the  background  in  the  data  analysis.  In  shRNA  experiments,  
after  evaluation  of  knockdown  efficiency,  cells  were  tested  for  viability  and  caspase  3/7  
activity.  Cells  were  seeded  in  96-­‐‑well  clear-­‐‑bottom  white  plates  at  a  density  of  10,000  
cells  per  well  and  incubated  with  complete  medium  containing  5  µμg/ml  puromycin  at  
37°C,  5%  CO2.  Cell  viability  and  caspase  3/7  activity  were  accessed  as  described  above.  
4.2 Results 
4.2.1 shRNA knockdown of SMO produces minor effects on LSCC 
survival. 
The  universal  expression  and  the  ability  to  target  SMO  with  multiple  available  
inhibitors  prompted  us  to  investigate  the  importance  of  SMO  in  LSCC  cells.  As  
demonstrated  in  Figure  15,  lentiviral-­‐‑mediated  expression  of  two  independent  SMO  
shRNA  constructs  successfully  reduced  the  SMO  mRNA  level  by  70~90%  in  four  cell  
lines  in  comparison  to  the  non-­‐‑targeting  control  (ShNT).  However,  only  minor  effects  on  
cell  viability  and  apoptosis  were  observed  in  these  cells  (Figure  16A,  B),  indicating  a  




Figure  15:  shRNA  knockdown  of  SMO  in  LSCC  cells  
Change  of  GAPDH-­‐‑normalized  SMO  mRNA  level  by  real-­‐‑time  PCR  following  
lentiviral  shRNA  knockdown.  Non-­‐‑targeting  shRNA  control  (shNT)  or  2  independent  
shRNAs  (SMO  sh1,  2,  3)  targeting  SMO  were  used  in  each  cell  line.  Data  were  
normalized  to  shNT  control  and  represent  the  mean  ±  SD  of  3  independent  experiments.  





Figure  16:  Measurements  of  cell  viability  and  apoptosis  after  SMO  knockdown  
Viability  (A)  and  apoptosis  (B)  were  evaluated  in  cells  after  SMO  knockdown  by  
using  ApoLive-­‐‑Glo  Multiplex  Assay  (Promega).  Data  were  normalized  to  shNT  control  
and  represent  the  mean  ±  SD  of  3  independent  experiments.  
 
4.2.2 SMO deletion produces minimal influence on downstream HH-
GLI signaling in LSCC cells. 
We  next  examined  the  expression  level  of  HH  targets  downstream  of  SMO.  As  
shown  in  Figure  17A,  SMO  knockdown  caused  a  moderate  decrease  of  PTCH1  mRNA  in  
NCI-­‐‑H520  and  NCI-­‐‑H226,  whereas  no  reduction  of  PTCH1  mRNA  was  seen  in  NCI-­‐‑
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H226  and  SK-­‐‑MES-­‐‑1.  No  significant  reduction  of  HHIP  mRNA  in  any  of  four  cell  lines  
(Figure  17B).  These  data  suggest  a  minimal  role  for  SMO  in  regulating  LSCC  survival  via  
the  canonical  HH  pathway.  Interestingly,  loss  of  SMO  did  not  reduce  GLI2  mRNA  level  
in  three  GLI-­‐‑positive  cell  lines.  Instead,  we  noted  a  slight  increase  of  GLI2  mRNA  
(Figure  17C),  which  may  be  caused  by  compensatory  upregulation  of  GLI2  by  other  
SMO-­‐‑independent  mechanisms.  
4.2.3 SMO inhibitor GDC-0449 shows limited cytotoxicity in LSCC 
cells. 
Recently,  SMO  inhibitors  have  demonstrated  promising  anti-­‐‑tumor  activity  in  
clinical  treatments  of  medulloblastoma  and  basal  cell  carcinoma.  To  investigate  the  
feasibility  of  pharmacologically  targeting  SMO  in  LSCC,  we  studied  the  therapeutic  
potential  of  a  clinically  available  SMO  inhibitor,  GDC-­‐‑0449.  To  maintain  physiologic  
relevance  and  minimize  off-­‐‑target  toxicity,  we  assessed  the  efficacy  of  GDC-­‐‑0449  in  four  
LSCC  cell  lines  at  the  concentrations  of  2.5,  5  and  10  µμmol/L.  Cells  were  treated  in  
triplicate  with  either  DMSO  control  or  GDC-­‐‑0449  for  96  hours,  and  then  assayed  for  
viability  and  caspase  3/7  activation.  
As  shown  in  Figure  18A,  treatment  of  GDC-­‐‑0449  in  NCI-­‐‑H520  led  to  20%  
reduction  of  viable  cells  at  5  µμmol/L,  and  approximate  50%  reduction  at  10  µμmol/L.  NCI-­‐‑
H226  only  showed  a  moderate  15%  decrease  of  viable  cells  at  10  µμmol/L.  No  significant  
growth  inhibition  was  observed  in  SK-­‐‑MES-­‐‑1  and  NCI-­‐‑H2170  cells  treated  with  GDC-­‐‑
0449.  Consistently,  GDC-­‐‑0449  induced  limited  increase  of  caspase  3/7  activities  in  NCI-­‐‑
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H520  (1.3  fold  increase  at  5  µμmol/L  and  1.6  fold  increase  at  10  µμmol/L)  and  NCI-­‐‑H226  
(1.6  fold  increase  at  10  µμmol/L)  (Figure  18B).  Despite  the  universal  expression  of  SMO,  
GDC-­‐‑0449  showed  limited  growth  inhibition  and  apoptosis  induction  in  LSCC  cells,  
which  is  consistent  with  our  observations  in  SMO  knockdown  experiments.    
4.2.4 SMO suppression by GDC-0449 shows limited impacts on 
downstream HH-GLI signaling in LSCC cells. 
In  agreement  with  the  limited  growth  inhibition,  GDC-­‐‑0449  only  caused  modest  
reduction  of  PTCH1  mRNA  in  NCI-­‐‑H226  cells,  which  suggested  that  GDC-­‐‑0449  failed  to  
suppress  downstream  signaling  in  these  cells  (Figure  19A).  Among  three  GLI-­‐‑positive  
cell  lines,  GDC-­‐‑0449  led  to  slight  decrease  of  GLI2  mRNA  only  in  NCI-­‐‑H226  and  SK-­‐‑
MES-­‐‑1  (Figure  19B).  This  finding  again  demonstrated  that  GDC-­‐‑0449  was  unable  to  
block  the  HH-­‐‑GLI  signaling  downstream  of  SMO,  indicating  a  minimal  role  of  SMO  in  




Figure  17:  Expression  of  HH  downstream  target  genes  after  SMO  knockdown  
Real-­‐‑time  PCR  analysis  showed  the  GAPDH-­‐‑normalized  mRNA  level  of  PTCH1  
(A),  HHIP  (B)  and  GLI2  (C)  after  SMO  knockdown.  Data  were  normalized  to  shNT  
control  and  represent  the  mean  ±  SD  of  3  independent  experiments.  
  41  
  
Figure  18:  GDC-­‐‑0449  treatment  in  LSCC  cells  
96-­‐‑hour  treatment  of  GDC-­‐‑0449  generated  limited  growth  inhibition  (A)  and  
apoptosis  (B).  Only  moderate  cytotoxicity  was  observed  in  NCI-­‐‑H520  and  NCI-­‐‑H226  
cells  at  10  µμmol/L.  Data  were  normalized  to  DMSO  control  and  represent  the  mean  ±  SD  
of  3  independent  experiments.  (Two-­‐‑tailed  t  test,  **:  p<0.01;  ***:  p<0.001)  
  
4.3 Summary 
The  universal  expression  of  SMO  and  its  importance  in  HH  signaling  
transduction  prompted  us  to  evaluate  the  effects  of  SMO  inhibition  in  LSCC  cells,  
because  there  are  multiple  clinically-­‐‑available  SMO  antagonists.  However,  neither  
genetic  nor  pharmacological  inhibition  of  SMO  produces  satisfying  growth  inhibition  
and  apoptosis  induction  in  four  LSCC  cell  lines.  Further  analysis  shows  that  suppression  
of  SMO  has  limited  impacts  on  downstream  HH  signaling,  evident  by  modest  changes  
of  expression  levels  of  HH  target  genes.  These  findings  collectively  demonstrate  a  
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dispensable  role  of  SMO  in  regulation  of  LSCC  cell  survival  via  mediating  HH-­‐‑GLI  
signaling.  In  fact,  multiple  studies  have  documented  SMO-­‐‑independent  regulation  of  
HH-­‐‑GLI  signaling  via  non-­‐‑canonical  pathways,  including  SUFU  loss-­‐‑of-­‐‑function  
mutations,  GLI  gain-­‐‑of-­‐‑function  mutations,  and  GLI  activation  by  PI3K/AKT  or  
RAS/MEK  signaling  pathways  (21,  60).  Interestingly,  amplification  of  GLI2  has  been  
proposed  as  putative  mechanism  responsible  for  resistance  to  SMO  inhibitors  (50).  Since  
we  have  observed  high  expression  of  GLI2  in  human  primary  LSCC,  as  well  as  in  LSCC  




Figure  19:  Expression  of  HH  target  genes  after  GDC-­‐‑0449  treatment  
Real-­‐‑time  PCR  showed  the  mRNA  level  of  PTCH1  (A)  and  GLI2  (B)  in  LSCC  cells  
treated  with  DMSO  or  10  µμmol/L  GDC-­‐‑0449  for  96  hours.  Gene  expressions  were  




5. GLI2 plays an important role in regulating LSCC cell 
survival and apoptosis. 
5.1 Materials and Methods 
5.1.1 Lentiviral production and transduction 
Lentiviral  shRNA  clones  (Sigma  Mission  RNAi)  targeting  GLI2  and  the  non-­‐‑
targeting  control  (SHC002)  were  purchased  from  Sigma-­‐‑Aldrich.  293T  cells  were  plated  
in  10-­‐‑cm  plates  24  hours  prior  to  transfection  in  DMEM  medium  containing  10%  fetal  
bovine  serum  (FBS)  without  antibiotics.  5  µμg  shRNA  plasmid,  4  µμg  psPAX2  and  1  µμg  
pCI-­‐‑VSVG  packaging  vectors  (Addgene)  were  co-­‐‑transfected  into  293T  cells  using  
Lipofectamine  2000  Reagent  (Invitrogen).  Viral  supernatants  were  collected,  centrifuged  
and  filtered  with  0.45  µμm  PES  Sterile  Syringe  Filter.  Target  cells  were  plated  and  
incubated  at  37°C,  5%  CO2  overnight,  and  changed  to  medium  containing  lentivirus  and  
8  µμg/mL  polybrene.  Control  plates  were  incubated  with  medium  containing  8  µμg/mL  
polybrene.  Cells  were  changed  to  fresh  culture  medium  24  hours  after  infection.  
Puromycin  selection  (5  µμg/ml)  was  started  48  hours  post  infection  and  continued  for  4~5  
days  until  no  viable  cells  were  observed  in  control  plates.  Once  decreased  expression  of  
the  targeted  gene  was  confirmed,  cells  were  used  for  subsequent  experiments.  Stable  
expression  of  non-­‐‑targeting  control  or  GLI2  shRNAs  was  ensured  by  culturing  cells  in  
the  presence  of  puromycin.  Sequences  of  shRNA  constructs  are  provided  as  below:  
GLI2  sh1  (5’-­‐‑  CCGGCCAACGAGAAACCCTACATCTCTCGAGAGATGTAGGGT  
TTCTCGTTGGTTTTTG-­‐‑3’)  
  45  
GLI2  sh2  (5’-­‐‑CCGGCACTCAAGGATTCCTGCTCATCTCGAGATGAGCAGGAA  
TCCTTGAGTGTTTTTG-­‐‑3’)  
GLI2  sh3  (5’-­‐‑CCGGGCTCTACTACTACGGCCAGATCTCGAGATCTGGCCGTA  GTA  
GTAGAGCTTTTTG-­‐‑3’)  
5.1.2 Western analysis  
Total  cellular  lysates  were  prepared  by  using  RIPA  buffer  (Sigma)  with  protease  
inhibitor  cocktail  (Sigma)  and  PhosSTOP  (Roche).  Protein  concentrations  were  
determined  by  Micro  BCA  Protein  Assay  Kit  (Thermo  Scientific).  Proteins  were  
separated  on  the  NuPAGE  4-­‐‑12%  Bis-­‐‑Tris  Gel  (Life  Technologies)  and  transferred  using  
Invitrolon  PVDF  Filter  Paper  Sandwich.  Membranes  were  blocked  with  5%  nonfat  dry  
milk  or  5%  BSA  in  0.1%TBST  for  1  hour  in  room  temperature,  then  incubated  with  
primary  antibody  overnight  at  4°C.  They  were  subsequently  washed  with  0.1%TBST  and  
incubated  with  the  secondary  antibody  for  1  hour  at  room  temperature.  Western  
Lightning-­‐‑  ECL  (PerkinElmer)  was  used  to  develop  the  membranes.  Antibodies  against  
GLI2  and  GAPDH  were  purchased  from  Abcam,  Cleaved  Caspase-­‐‑3  and  Cleaved  PARP  
from  Cell  Signaling  Technology,  and  CCND1  from  BD  Biosciences.  
5.1.3 RNA isolation and Real-time PCR 
Total  RNA  was  isolated  using  the  Qiagen  RNeasy  Mini  Kit,  treated  with  DNase  I  
(Invitrogen)  and  converted  to  cDNA  using  iScript  cDNA  Synthesis  Kit  (BIO-­‐‑RAD).  Real-­‐‑
time  PCR  was  performed  using  TaqMan  Gene  Expression  Master  Mix  on  an  Eppendorf  
  46  
Mastercycler,  and  raw  data  were  analyzed  by  Realplex  software.  TaqMan  probes  for  
PTCH1,  GLI2,  HHIP1,  and  GAPDH  were  purchased  from  Applied  Biosystems.    
5.1.4 Assessment of cell viability and caspase 3/7 activity 
In  GANT61  treatment,  cells  were  seeded  in  96-­‐‑well  clear-­‐‑bottom  white  plates  
(Corning  Costar)  at  a  density  of  10,000  cells  per  well  and  incubated  with  complete  
medium  overnight  at  37°C,  5%  CO2.  The  following  day,  cells  were  changed  into  0.5%  
FBS-­‐‑containing  medium  with  either  DMSO  control  or  GANT61  (Sigma-­‐‑Aldrich)  at  
designated  concentrations  (0.1%  final  DMSO  concentration)  as  triplicates  and  treated  for  
96  hours.  At  the  end  of  treatment,  cell  viability  and  caspase  3/7  activity  were  determined  
by  using  ApoLive-­‐‑Glo  Multiplex  Assay  (Promega)  according  to  the  manufacturer’s  
instructions.  Briefly,  viability  reagent  was  added  into  all  wells  and  gently  mixed.  After  
1.5-­‐‑hour  incubation  at  37°C,  fluorescence  was  measured  at  the  wavelength  set  355EX/  
520EM  by  a  FLUOstar  Omega  Microplate  reader.  Later,  Caspase-­‐‑Glo®  3/7  Reagent  was  
added  to  all  wells  and  gently  mixed.  Luminescence  was  measured  after  1-­‐‑hour  
incubation  at  room  temperature.  The  reading  of  blank  control  was  subtracted  from  
readings  of  other  wells  as  the  background  in  the  data  analysis.  In  shRNA  experiments,  
after  evaluation  of  knockdown  efficiency,  cells  were  tested  for  viability  and  caspase  3/7  
activity.  Cells  were  seeded  in  96-­‐‑well  clear-­‐‑bottom  white  plates  at  a  density  of  10,000  
cells  per  well  and  incubated  with  complete  medium  containing  5  µμg/ml  puromycin  at  
37°C,  5%  CO2.  Cell  viability  and  caspase  3/7  activity  were  accessed  as  described  above.  
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5.2 Results 
5.2.1 Targeting GLI2 with shRNAs inhibits LSCC cell growth and 
induces extensive apoptosis. 
Since  GLI1  is  hardly  detectable  and  high  level  of  GLI2  is  consistently  expressed  in  
three  cell  lines  and  across  human  LSCC  tumors,  we  focused  on  GLI2.  Independent  
lentiviral-­‐‑based  GLI2  shRNAs  achieved  satisfactory  knockdown  of  GLI2  protein  in  all  
three  GLI2-­‐‑positive  lines  (Figure  20).  Knockdown  of  GLI2  reduced  the  protein  level  of  
the  GLI  target  Cyclin  D1  (CCND1),  which  is  a  direct  target  of  GLI2  that  regulates  cell  
cycle  and  promotes  cell  proliferation  (Figure  20).  Loss  of  GLI2  also  induced  extensive  
apoptosis,  demonstrated  by  strong  induction  of  cleaved  caspase-­‐‑3  and  cleaved  PARP  
(Figure  20).  These  molecular  changes  were  consistent  with  the  strong  inhibition  of  cell  
proliferation  and  survival  (Figure  21A),  as  well  as  extensive  apoptosis  evident  by  
elevated  caspase  3/7  activity  (Figure  21B).  These  data  collectively  demonstrate  an  
important  role  of  GLI2  in  regulating  LSCC  cell  survival,  raising  the  possibility  that  GLI2  
is  a  therapeutic  target  in  human  LSCC.    
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Figure  20:  shRNA  knockdown  of  GLI2  in  LSCC  cells  
Western  blots  showing  GLI2  knockdown  by  independent  shRNAs  (GLI2  sh1,  2,  
3).  GLI2  shRNAs  significantly  reduced  GLI2  protein  levels,  in  comparison  to  the  shNT  
control.  GLI2  knockdown  also  caused  induction  of  cleaved  caspase-­‐‑3,  cleaved  PARP  and  
reduction  of  CCND1.  GAPDH  was  used  as  the  loading  control.  A  representative  




Figure  21:  Measurements  of  viability  and  apoptosis  in  LSCC  cells  after  GLI2  
knockdown  
Knockdown  of  GLI2  in  LSCC  cells  significantly  reduced  proliferation  (A)  and  
induced  apoptosis  (B).  Data  were  normalized  to  shNT  control  and  represent  the  mean  ±  
SD  of  3  independent  experiments.  (Two-­‐‑tailed  t  test,  **:  p<0.01;  ***:    p<0.001)    
  
5.2.2 GLI inhibitor GANT61 leads to significant growth inhibition and 
apoptosis in LSCC cells. 
In  order  to  study  the  therapeutic  potential  of  pharmacologically  targeting  GLI  
proteins  in  LSCC,  we  employed  GANT61,  a  newly  described  small  molecule  that  
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selectively  blocks  both  GLI1  and  GLI2-­‐‑  mediated  transcription.  The  originally  reported  
IC50  of  GNAT61  to  reduce  GLI-­‐‑luciferase  reporter  activity  is  ≈5  µμmol/L  (51),  and  the  
commonly  used  concentration  of  GANT61  in  vitro  ranging  from  5~30  µμmol/L  (52,  53).  To  
maintain  physiologic  relevance  and  minimize  off-­‐‑target  toxicity,  we  assessed  the  efficacy  
of  GANT61  on  four  LSCC  cell  lines  at  the  concentrations  of  2.5,  5  and  10  µμmol/L  (Figure  
22A).  Cells  were  treated  in  triplicate  with  either  DMSO  control  or  GANT61  for  96  hours,  
and  then  assayed  for  viability  and  caspase  3/7  activation  with  Apolive-­‐‑Glo  (Promega),  as  
described  in  Materials  and  Methods.  The  IC50  of  growth  inhibition  in  this  assay  for  
three  GLI-­‐‑positive  cell  lines  was  approximately  5  µμmol/L.  Both  NCI-­‐‑H520  and  NCI-­‐‑
H226  showed  a  55%  reduction  at  5  µμmol/L  and  90%  reduction  at  10  µμmol/L  in  cell  
survival.  SK-­‐‑MES-­‐‑1  displayed  approximate  40%  and  60%  decrease  in  viability  at  5  and  
10  µμmol/L,  respectively.  As  expected,  GANT61  exhibited  little  cytotoxicity  in  the  GLI-­‐‑
negative  cell  line,  NCI-­‐‑H2170,  in  line  with  the  high  selectivity  of  this  GLI  inhibitor.  
Consistently,  increased  apoptosis  was  seen  in  GLI-­‐‑positive  cell  lines  at  corresponding  
GANT61  concentrations:  NCI-­‐‑H520  (1.8~2.3  fold),  NCI-­‐‑H226  (2.8~4  fold)  and  SK-­‐‑MES-­‐‑1  
(2.4~2.6  fold).  No  increased  caspase  3/7  activity  was  detected  in  GLI-­‐‑negative  NCI-­‐‑H2170  
cells  after  GANT61  treatment  (Figure  22B).  In  contrast  to  GDC-­‐‑0449,  GANT61  showed  
greater  growth  inhibition  and  apoptosis  induction  at  equimolar  concentrations  at  the  
same  time  point,  demonstrating  a  higher  efficacy  than  GDC-­‐‑0449  in  a  dose-­‐‑dependent  
manner  in  all  GLI-­‐‑positive  cell  lines.  Our  results  suggest  that  targeting  the  HH  signaling  
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pathway  at  the  level  of  GLI  proteins  may  be  more  effective  than  targeting  either  the  
ligand  SHH  or  the  receptor  SMO  in  LSCC,  potentially  due  to  the  existence  of  the  ligand  
or  receptor  independent  pathway  activation  as  reported  in  previous  studies.    
  
  
Figure  22:  GANT61  treatment  in  LSCC  cells  
96-­‐‑hour  treatment  of  GANT61  significantly  reduced  cell  survival  (A)  and  
induced  extensive  apoptosis  (B)  in  all  GLI-­‐‑positive  cell  lines.  GLI-­‐‑negative  NCI-­‐‑H2170  
was  not  affected  by  GANT61.  Data  were  normalized  to  DMSO  control  and  represent  the  




5.2.3 GANT61 treatment reduces the expression of HH-GLI target 
genes.  
The  influence  of  GANT61  on  the  expression  of  HH  target  genes  was  
subsequently  determined  in  GLI-­‐‑positive  cell  lines  for  up  to  96  hours  after  treatment.  
Real-­‐‑time  PCR  analysis  showed  that  10  µμmol/L  GANT61  treatment  resulted  in  moderate  
reduction  of  HH  downstream  targets  (GLI2,  PTCH1  and  HHIP)  in  NCI-­‐‑H520  with  a  
greater  decrease  in  NCI-­‐‑H226  and  SK-­‐‑MES-­‐‑1  in  comparison  to  DMSO  control  (Figure  
23A~C).  Western  analysis  confirmed  the  reduction  of  GLI2  protein  in  GANT61-­‐‑treated  
cells  (Figure  24).  Consistent  with  previous  apoptosis  assay,  cleaved  caspase-­‐‑3  was  
detected  in  cells  receiving  GANT61,  evidence  of  the  extensive  apoptosis  induced  by  
GANT61  in  GLI-­‐‑positive  cells  (Figure  24).  The  expression  of  CCND1  was  also  decreased  
after  GANT61  treatment  in  agreement  with  GLI2  reduction,  indicating  an  impaired  cell  
proliferation  in  addition  to  increased  cell  death  (Figure  24).    
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Figure  23:  Expression  of  HH  target  genes  after  GANT61  treatment  
Exposure  to  GANT61  reduced  mRNA  levels  of  GLI  targets  in  GLI-­‐‑positive  cell  
lines:  NCI-­‐‑H520  (A),  NCI-­‐‑H226  (B),  SK-­‐‑MES-­‐‑1  (C).  Cells  were  treated  with  DMSO  
control  or  10  µμmol/L  GANT61  for  96  hours.  Gene  expressions  were  normalized  to  
endogenous  GAPDH  in  each  cell  line.  Data  represent  the  mean  ±  SD  of  3  independent  




Figure  24:  GANT61  reduced  expression  of  proliferation-­‐‑  and  apoptosis-­‐‑  related  
genes  
96-­‐‑hour  treatment  of  GANT61  reduced  expression  of  GLI2  and  CCND1,  and  
induced  expression  of  cleaved  caspase-­‐‑3  and  cleaved  PARP,  in  comparison  to  DMSO  
control.  GAPDH  was  used  as  the  loading  control.  A  representative  Western  blot  from  3  
independent  experiments  is  shown.    
  
5.3 Summary 
We  have  observed  that  suppression  of  SMO  failed  to  reduce  GLI2  expression,  
and  showed  no  inhibition  of  downstream  HH-­‐‑GLI  signaling.  It  suggested  the  existence  
of  non-­‐‑canonical  regulation  of  GLI2  in  LSCC  cells  via  SMO-­‐‑independent  mechanisms.  
Therefore,  we  went  on  to  test  the  importance  of  GLI2  in  regulation  of  LSCC  cell  survival  
and  cell  death.  GLI2  suppression  by  both  shRNA  knockdown  and  GANT61  treatment  
has  resulted  in  strong  growth  inhibition  and  apoptosis  induction  in  GLI2-­‐‑expressing  
  55  
LSCC  cells.  Expression  of  HH  target  genes  downstream  of  GLI2,  PTCH1  and  HHIP,  has  
also  been  significantly  reduced,  indicating  successful  blockage  of  HH-­‐‑GLI  signaling.  In  
addition,  we  have  observed  decreased  CCND1  and  induction  of  cleaved  Caspase-­‐‑3,  
cleaved  PARP,  which  are  consistent  with  reduced  cell  viability  and  increased  cell  death.  
While  SMO  plays  a  dispensable  role  in  LSCC  cells,  GLI2  is  required  for  cell  survival  and  
proliferation  via  mediating  HH-­‐‑GLI  signaling,  which  raises  the  possibility  that  GLI2  
may  be  a  therapeutic  target  in  LSCC.    Importantly,  GANT61  demonstrates  great  in  vitro  
efficacy  in  growth  inhibition  and  apoptosis  induction  in  GLI-­‐‑positive  LSCC  cells,  and  
displays  high  degree  of  selectivity  by  showing  no  impacts  in  GLI-­‐‑negative  cells.  In  order  
to  further  test  the  potential  of  GLI2  inhibition  in  clinical  care,  we  continue  to  investigate  
the  efficacy  of  GANT61  in  vivo.  
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6. GLI inhibitor GANT61 suppresses GLI-positive tumor 
progression in vivo. 
6.1 Materials and Methods 
6.1.1 Xenograft and tumor treatment 
106  NCI-­‐‑H520  cells,  106  NCI-­‐‑H2170  cells  or  5×106  NCI-­‐‑H226  cells  were  suspended  
in  a  total  volume  of  100  µμl  of  a  1:1  mixture  of  RPMI  1640  medium:  Matrigel  (BD  
Biosciences).  Cells  were  injected  subcutaneously  in  the  right  posterior  flank  of  6~8  week  
C.129S7  (B6)-­‐‑Rag1tm1Mom/  J  (Rag1-­‐‑/-­‐‑)  mice.  Tumors  were  grown  until  they  reached  a  
median  size  of  ≈250  mm3  (NCI-­‐‑H520),  ≈230  mm3  (NCI-­‐‑H2170),  and  ≈150  mm3  (NCI-­‐‑
H226).  Animals  were  randomly  divided  into  groups  and  treated  with  solvent  only  (corn  
oil:  ethanol,  4:1)  or  GANT61  in  solvent  (50  mg/kg).  Treatments  were  given  every  other  
day  for  20  days  by  intraperitoneal  injection.  Tumor  volumes  were  calculated  by  the  
formula  0.52×length×(width)2.  At  the  end  of  treatment,  tumors  were  removed,  weighed  
and  processed  for  subsequent  analysis.  All  animal  experiments  were  approved  by  and  
conformed  to  the  policies  and  regulations  of  Institutional  Animal  Care  and  Use  
Committees  at  Duke  University.  GANT61  was  purchased  from  Sigma-­‐‑Aldrich.  
6.1.2 Tissue mRNA collection and quantitative real-time PCR 
Fresh  animal  tissues  were  first  excised  and  cut  into  slices  less  than  0.5  cm  thick,  
and  then  immediately  and  completely  submerged  in  the  collection  tubes  containing  
RNAlater  RNA  stabilization  Reagent  (Qiagen).  Before  RNA  isolation,  tissues  were  
removed  from  RNAlater  RNA  stabilization  Reagent,  and  then  disrupted  and  
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homogenized.  Total  RNA  was  isolated  using  the  Qiagen  RNeasy  Mini  Kit,  treated  with  
DNase  I  (Invitrogen)  and  converted  to  cDNA  using  iScript  cDNA  Synthesis  Kit  (BIO-­‐‑
RAD).  Real-­‐‑time  PCR  was  performed  using  TaqMan  Gene  Expression  Master  Mix  on  an  
Eppendorf  Mastercycler,  and  raw  data  were  analyzed  by  Realplex  software.  TaqMan  
probes  for  PTCH1,  HHIP  and  GAPDH  were  purchased  from  Applied  Biosystems.  
6.2 Results 
6.2.1 GANT61 suppresses tumor growth of NCI-H520 in vivo. 
Currently,  there  are  no  available  transgenic  murine  models  that  faithfully  
recapitulate  human  LSCC.  While  SOX2  is  reported  to  be  an  amplified  lineage-­‐‑survival  
oncogene  in  human  LSCC  (6),  overexpression  of  Sox2  driven  by  several  lung-­‐‑cell-­‐‑type  
specific  Cre-­‐‑promoters  in  mice  produced  adenocarcinoma  (9).  The  K-­‐‑ras  G12D  mutation  
combined  with  homozygous  Lkb1  inactivation  generated  a  mixture  of  NSCLC,  including  
LSCC,  adenocarcinoma  and  large  cell  carcinoma  (61).  However,  K-­‐‑Ras  mutation  is  rarely  
seen  in  LSCC  patients  (1).  In  recent  years,  patient-­‐‑derived  xenograft  models  of  LSCC  are  
of  great  interests,  but  have  not  achieved  satisfactory  progress.  Therefore,  we  used  a  
xenograft  model  of  representative  human  LSCC  cell  lines  to  determine  the  efficacy  of  
GANT61  in  blocking  HH-­‐‑GLI  signaling  and  subsequent  tumor  growth  in  vivo.  
We  first  studied  the  in  vivo  efficacy  of  GANT61  on  the  xenografts  of  NCI-­‐‑H520,  
which  represents  the  classical  subtype  of  LSCC  and  has  high  level  of  GLI2.  NCI-­‐‑H520  
cancer  cells  were  injected  subcutaneously  into  the  right  flank  of  immune  deficient  Rag1-­‐‑
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/-­‐‑  mice.  Mice  were  randomly  divided  into  two  groups  when  tumors  reached  median  size  
of  ≈250  mm3  (n=8  for  each  group).  We  began  treatment  with  either  solvent  control  or  
GANT61  at  a  previously  described  dose  of  50  mg/kg  (51).  In  order  to  avoid  severe  
ulcerations  at  the  injection  sites  that  occurred  in  a  previous  study,  all  injections  were  
given  intraperitoneally  every  other  day.  During  a  20-­‐‑day  treatment  period,  suppression  
of  NCI-­‐‑H520  tumor  growth  was  observed  in  the  groups  receiving  GANT61  (Figure  25).  
Tumors  of  each  group  were  removed  and  weighed  at  the  end  of  the  treatment.  GANT61  
led  to  a  significant  40%  reduction  of  tumor  weight  for  NCI-­‐‑H520  in  comparison  to  the  
solvent  control  (Figure  26).  No  adverse  side  effects,  such  as  weight  loss,  ulcerations,  or  
general  illness  of  the  animals,  were  observed  in  either  group  during  the  entire  treatment.  
Quantitative  real-­‐‑time  PCR  analysis  of  GLI  targets  in  tumors  confirmed  that  GANT61  
significantly  reduced  the  expression  of  the  target  genes  PTCH1  and  HHIP  (Figure  27),  
confirming  an  on-­‐‑target  anti-­‐‑tumor  activity  of  GANT61  in  vivo.  These  data  demonstrate  







Figure  25:  Growth  curve  of  NCI-­‐‑H520  during  GANT61  treatment  
Growth  of  NCI-­‐‑H520  xenografts  during  treatment  period  is  shown  as  the  mean  ±  
SD  (n=8).  Tumor  volumes  were  calculated  by  the  formula  0.52×length×(width)2.  Data  
were  analyzed  by  two-­‐‑tailed  t  test.  (**:  p<0.01;  ***:  p<0.001.)  
  
  
Figure  26:  Measurement  of  NCI-­‐‑H520  tumor  weight  at  the  end  of  treatment  
Tumors  from  control  and  GANT61  treated  groups  (n=8)  were  removed  and  




Figure  27:  Expression  level  of  PTCH1  and  HHIP  in  NCI-­‐‑H520  Xenografts  
Quantification  of  PTCH1  and  HHIP  mRNA  by  real-­‐‑time  PCR  in  treated  tumors  
for  NCI-­‐‑H520  (n=4).  Values  were  normalized  against  GAPDH.  Shown  is  the  mean  ±  SD  
of  independent  tumors  in  each  group.  Data  were  analyzed  by  two-­‐‑tailed  t  test  (*:  p<0.05).  
  
6.2.2 GANT61 inhibits tumor growth of NCI-H226 in vivo. 
Next,  we  evaluated  the  in  vivo  efficacy  of  GANT61  on  the  xenografts  of  NCI-­‐‑
H226.  Although  NCI-­‐‑H226  is  predicted  to  be  the  secretory  subtype  of  LSCC,  it  exhibits  
endogenous  high  level  of  GLI2  expression.  NCI-­‐‑H226  cancer  cells  were  injected  
subcutaneously  into  the  right  flank  of  immune  deficient  Rag1-­‐‑/-­‐‑  mice.  Mice  were  
randomly  divided  into  two  groups  when  tumors  reached  median  size  of  ≈150  mm3  (n=5  
for  each  group).  Treatment  was  started  with  either  solvent  control  or  GANT61  (50  
mg/kg)  by  intraperitoneal  injection  every  other  day.  During  a  20-­‐‑day  treatment  period,  
inhibition  of  tumor  growth  was  observed  in  NCI-­‐‑H226  xenograft  tumors  receiving  
GANT61  (Figure  28).  In  the  end  of  treatment,  GANT61  resulted  in  a  significant  40%  
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reduction  of  NCI-­‐‑H226  tumor  weight  when  compared  with  tumors  receiving  solvent  
control  (Figure  29).  No  adverse  side  effects,  such  as  weight  loss,  ulcerations,  or  general  
illness  of  the  animals,  were  observed  in  either  group  during  the  entire  treatment.  
Expression  of  PTCH1  and  HHIP  in  GANT61-­‐‑treated  tumors  was  significantly  decreased  
in  comparison  to  the  control  group  (Figure  30).  Taken  together,  these  studies  show  that  
GANT61  is  effective  in  suppressing  the  progression  of  secretory  LSCC  tumors  with  high  
GLI2  via  blockage  of  HH-­‐‑GLI  signaling.  
  
  
Figure  28:  Growth  curve  of  NCI-­‐‑H226  during  GANT61  treatment  
Growth  of  NCI-­‐‑H226  xenografts  during  treatment  period  is  shown  as  the  mean  ±  
SD  (n=5).  Tumor  volumes  were  calculated  by  the  formula  0.52×length×(width)2.  Data  




Figure  29:  Measurement  of  NCI-­‐‑H226  tumor  weight  at  the  end  of  treatment  
Tumors  from  control  and  GANT61  treated  groups  (n=5)  were  removed  and  
weighed  at  the  end  of  treatment,  and  data  were  analyzed  by  two-­‐‑tailed  t  test.    
  
  
Figure  30:  Expression  level  of  PTCH1  and  HHIP  in  NCI-­‐‑H226  xenografts  
Quantification  of  PTCH1  and  HHIP  mRNA  by  real-­‐‑time  PCR  in  treated  tumors  
for  NCI-­‐‑H226  (n=5).  Values  were  normalized  against  GAPDH.  Shown  is  the  mean  ±  SD  




6.2.3 Growth of GLI-negative NCI-H2170 was not affected by GANT61 
in vivo. 
Off-­‐‑target  toxicity  is  a  big  concern  in  therapeutic  agent  development.  In  order  to  
test  the  selectivity  and  efficacy  of  GANT61  in  vivo,  a  xenograft  model  of  GLI-­‐‑negative  
NCI-­‐‑H2170  was  established  by  injecting  cancer  cells  subcutaneously  into  the  right  flank  
of  immune  deficient  Rag1-­‐‑/-­‐‑  mice.  Mice  were  randomly  divided  into  two  groups  when  
tumors  reached  median  size  of  ≈230  mm3  (n=5  for  each  group).  We  began  treatment  with  
either  solvent  control  or  GANT61  (50  mg/kg)  by  intraperitoneal  injection  every  other  
day  as  performed  in  NCI-­‐‑H520  and  NCI-­‐‑H226  xenografts.  During  a  20-­‐‑day  treatment,  
however,  no  significant  difference  of  tumor  growth  was  found  in  the  NCI-­‐‑H2170  
xenograft  (Figure  31).  In  contrast  to  GLI-­‐‑positive  NCI-­‐‑H520  and  NCI-­‐‑H226,  no  
significant  reduction  of  tumor  volume  or  tumor  weight  was  observed  in  the  GLI-­‐‑
negative  NCI-­‐‑H2170  tumors  (Figure  32),  suggesting  a  specific  anti-­‐‑tumor  efficacy  of  
GANT61  in  GLI  overexpressing  cancer  cells.  Consistently,  expression  level  of  GLI  
targets,  PTCH1  and  HHIP,  was  not  significantly  changed  in  GANT61-­‐‑treated  NCI-­‐‑H2170  
xenograft  tumors  (Figure  33).    
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Figure  31:  Growth  curve  of  NCI-­‐‑H2170  during  GANT61  treatment  
Growth  of  NCI-­‐‑H2170  xenografts  during  treatment  period  is  shown  as  the  mean  
±  SD  (n=5).  Tumor  volumes  were  calculated  by  the  formula  0.52×length×(width)2.  Data  
were  analyzed  by  two-­‐‑tailed  t  test.  No  significant  difference  of  tumor  growth  was  
observed  between  control  group  and  GANT61  group.  
  
  
Figure  32:  Measurement  of  NCI-­‐‑H2170  tumor  weight  at  the  end  of  treatment  
Tumors  from  control  and  GANT61  treated  groups  (n=5)  were  weighed  at  the  end  
of  treatment.  Data  were  analyzed  by  two-­‐‑tailed  t  test,  NS:  not  significant.    
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Figure  33:  Expression  Level  of  PTCH1  and  HHIP  in  NCI-­‐‑H2170  xenografts  
Quantification  of  PTCH1  and  HHIP  mRNA  by  real-­‐‑time  PCR  in  treated  tumors  
for  NCI-­‐‑H2170  (n=5).  Values  were  normalized  against  GAPDH.  Shown  is  the  mean  ±  SD  




Based  on  our  in  vitro  studies,  we  expected  that  the  in  vivo  tumor  growth  of  SK-­‐‑
MES-­‐‑1  would  also  be  suppressed  by  GANT61  treatment.  In  our  studies,  5✕106  SK-­‐‑MES-­‐‑1  
cells  with  Matrigel  were  subcutaneously  injected  into  the  right  flank  of  Rag1-­‐‑/-­‐‑  mice  
(n=10).  However,  after  more  than  10  weeks,  no  palpable  tumor  was  established  in  these  
mice.  This  experiment  was  repeated  in  another  four  mice,  but  again  no  tumors  were  
successfully  established  for  this  cell  line.  This  is  not  surprising  because  we  also  noticed  
that  in  vitro  growth  of  SK-­‐‑MES-­‐‑1  is  much  slower  than  the  other  three  cell  lines.  Since  this  
cell  line  appeared  to  be  difficult  to  form  xenograft  tumors,  we  chose  to  test  two  GLI-­‐‑
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positive  cell  lines,  NCI-­‐‑H520  and  NCI-­‐‑H226,  as  well  as  one  GLI-­‐‑negative  cell  line  NCI-­‐‑
H2170.  
Consistent  with  the  in  vitro  studies,  GANT61  suppresses  in  vivo  tumor  
progression  of  GLI-­‐‑positive  LSCC  cell  lines,  NCI-­‐‑H520  and  NCI-­‐‑H226,  during  treatment  
period,  and  leads  to  significant  reduction  of  final  tumor  weights.  As  expected,  growth  of  
GLI-­‐‑negative  NCI-­‐‑H2170  xenografts  is  not  affected  by  GANT61,  again  demonstrating  
the  high  selectivity  of  GANT61.  Expression  of  HH-­‐‑GLI  target  genes,  PTCH1  and  HHIP,  
in  NCI-­‐‑H520  and  NCI-­‐‑H226  is  significantly  decreased,  but  is  no  influenced  in  NCI-­‐‑
H2170,  suggesting  that  GANT61  maintains  robust  efficacy  and  selectivity  of  inhibiting  
HH-­‐‑GLI  signaling  in  vivo.  These  data  suggest  the  potential  clinical  application  of  GLI  
inhibition  by  GANT61  in  treating  patients  with  HH-­‐‑GLI  active  LSCC.  
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7. Conclusion, discussion and future directions 
7.1 Conclusions 
Aberrant  HH  signaling  has  been  implicated  in  a  diverse  spectrum  of  human  
cancers.  Previous  studies  have  reported  hyperactive  HH  signaling  in  a  subset  of  LSCC,  
but  they  failed  to  address  the  complexity  and  heterogeneity  of  the  disease.  Four  distinct  
molecular  subtypes,  which  have  different  survival  outcomes,  patient  populations,  and  
biological  processes,  were  identified  by  gene  expression-­‐‑subtype  signatures  (19).    
In  the  recent  study  of  TCGA  (20),  we  found  that  the  HH  activation  is  associated  
with  the  classical  subtype  (~36%  of  LSCC),  and  approximate  55%  of  the  classical  subtype  
displayed  high  expression  of  GLI2.  A  consistent  pattern  was  observed  in  an  independent  
UNC  microarray  dataset.  This  observation  is  consistent  with  previous  
immunohistochemical  studies,  which  showed  high  activation  of  HH  signaling  in  
approximately  27%  of  LSCC  patients  (41,  42).  Among  all  four  subtypes,  the  classical  
subtype  has  the  highest  proportion  of  smokers  and  the  heaviest  smoking  history,  as  well  
as  the  greatest  overexpression  of  three  known  oncogenes  on  3q26  amplicon:  SOX2,  TP63  
and  PIK3CA  (19,  20).  While  GLI2  was  consistently  highly  expressed  in  the  classical  
subtype,  strong  positive  correlations  between  GLI2  and  the  three  best-­‐‑known  markers  of  
the  classical  subtype  on  chromosome  3q  were  observed,  together  suggesting  a  critical  
role  of  GLI2  in  LSCC,  as  found  in  SCC  in  other  organs  (44-­‐‑46).  If  the  hyperactive  HH-­‐‑GLI  
signaling  found  in  the  classical  subtype  of  LSCC  is  required  for  tumor  maintenance  and  
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progression,  suppressing  the  HH-­‐‑GLI  pathway  by  clinically-­‐‑available  inhibitors  may  be  
a  potent  targeted  therapy  to  treat  a  subset  of  LSCC  patients.  
Recent  development  of  multiple  SMO  inhibitors  for  human  administration  
prompted  us  to  test  the  potential  clinical  application  to  treat  LSCC  patients  by  targeting  
SMO.  However,  shRNAs  knockdown  of  SMO  showed  only  minor  effects  on  LSCC  cell  
survival  and  apoptosis,  with  little  effect  on  HH  downstream  target  gene  expression.  
Consistently,  GDC-­‐‑0449  produced  limited  cytotoxicity  despite  the  universal  expression  
of  SMO,  suggesting  the  existence  of  SMO-­‐‑independent  regulation  of  GLI  signaling.  The  
strong  and  unique  expression  pattern  of  GLI2  prompted  the  query  whether  it  is  
necessary  for  LSCC  tumor  progression.  Knockdown  of  GLI2  induced  apoptosis  and  
significant  growth  inhibition  in  GLI2-­‐‑positive  LSCC  cells,  demonstrating  an  essential  
role  of  GLI2  in  regulating  cell  viability  and  death.  Importantly,  the  GLI  inhibitor,  
GANT61,  effectively  blocked  GLI-­‐‑mediated  signal  transduction  and  suppressed  tumor  
growth  both  in  vitro  and  in  vivo.  Recent  studies  in  neuroblastoma  (55)  and  chronic  
lymphocytic  leukemia  (56)  also  showed  that  GANT61  effectively  suppressed  tumor  
progression  in  cancers  insensitive  to  SMO  inhibition.  Interestingly,  amplification  of  GLI2  
or  CCND1  have  been  proposed  as  additional  mechanisms  responsible  for  resistance  to  
SMO  inhibitors  (50),  and  GANT61  treatment  significantly  reduced  expression  of  GLI2  
and  CCND1  in  LSCC  cells.    
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Figure  34:  A  hypothetical  model  of  the  HH-­‐‑GLI  pathway  in  LSCC  
Canonical  HH-­‐‑GLI  signaling  is  activated  by  the  ligand-­‐‑dependent  activation  of  
SMO.  However,  direct  and  specific  inhibition  of  SMO  in  LSCC  cells  has  little  impacts  on  
downstream  signaling  and  cell  survival.  In  contrast,  direct  knockdown  or  specific  
blockage  of  GLI2  results  in  growth  inhibition  and  apoptosis  induction,  suggesting  a  
critical  role  of  GLI2  in  LSCC.  GLI2  may  be  activated  in  a  cell  autonomous  fashion  and/or  
through  non-­‐‑canonical  HH  signaling.      
  
As  summarized  in  Figure  34,  we  have  identified  SMO-­‐‑independent  GLI  
regulation  in  LSCC,  and  demonstrated  that  GLI2  is  important  for  cell  survival  and  
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proliferation.  Treatment  options  for  LSCC  overall  are  disappointing.  Different  from  
standard-­‐‑of-­‐‑care  chemotherapy  or  small  molecule  inhibition  of  kinase  signaling  
cascades,  we  present  a  novel  and  potential  strategy  to  treat  a  subset  of  LSCC  patients  by  
targeting  the  GLI  transcriptional  network.  Our  studies  also  highlight  the  need  for  agents  
that  suppress  GLI  effectors  with  high  efficacy  and  selectivity.    
7.2 Discussion and Future Directions 
7.2.1 Non-canonical activation of GLI signaling in LSCC 
The  canonical  activation  of  HH-­‐‑GLI  signaling  is  initiated  by  the  binding  of  HH  
ligands  to  the  receptor  PTCH,  and  thus  relieves  the  repression  of  PTCH  on  SMO,  which  
further  triggers  a  series  of  cellular  events  and  leads  to  GLI  activation.  Interestingly,  we  
notice  that  the  expression  of  ligand  SHH  within  the  classical  subtype  varied  markedly  
and  was  not  significantly  different  between  subtypes.  The  expression  patterns  of  other  
two  HH  ligands,  IHH  and  DHH,  were  similar  to  SHH  (Figure  35).    These  data  indicate  
the  existence  of  ligand-­‐‑independent  GLI  activation  in  the  classical  subtype.  Genetic  
alterations,  including  loss  of  PTCH  function,  constitutively  active  SMO,  and  
amplification  of  GLI1/GLI2  have  been  reported  to  activate  downstream  HH  signaling  
independent  of  ligands  in  various  cancers.  Moreover,  GLI  function  can  be  modulated  in  
a  SMO-­‐‑independent  manner  by  PI3K/AKT  (30),  RAS-­‐‑MEK  signaling  (31,  32),  which  may  
contribute  to  the  hyperactive  HH-­‐‑GLI  signaling  in  LSCC  in  addition  to  canonical  HH  




Figure  35:  Expression  pattern  of  HH  ligands  in  four  LSCC  subtypes  of  the  
TCGA  cohort  
Tumor  samples  are  displayed  as  columns,  grouped  by  gene  expression  subtype.  
Selected  HH  ligands  are  shown  in  rows.  
  
While  RAS  mutation  is  rarely  seen  in  LSCC,  PIK3CA  copy  number  gains  and  loss  
of  PTEN  function  are  prevalent  in  the  classical  subtype  of  LSCC,  where  the  activation  of  
HH  signaling  was  observed.  GLI2  exhibits  a  strong  positive  correlation  with  PIK3CA  
expression.  It  has  been  shown  that  PI3K/AKT  pathway  positively  regulates  HH-­‐‑GLI  
signaling  by  inhibiting  Protein  Kinase  A  (PKA)-­‐‑mediated  degradation  of  GLI2  (30).  NCI-­‐‑
H520,  representing  the  classical  subtype  of  LSCC,  has  been  reported  to  harbor  PIK3CA  
amplification  and  PTEN  loss-­‐‑of-­‐‑function  mutation,  and  thus  has  endogenous  active  PI3K  
signaling  (62).  Growth  of  NCI-­‐‑H520  can  be  significantly  inhibited  by  a  pan  PI3K  
inhibitor  GDC-­‐‑0941  or  a  dual  PI3K/mTOR  inhibitor  GDC-­‐‑0980  both  in  vitro  and  in  vivo  
(62).  Our  preliminary  data  suggested  that  the  treatment  of  a  classical  PI3K  inhibitor  in  
NCI-­‐‑H520  cells  significantly  reduced  GLI2  mRNA  level.  Therefore,  an  attractive  
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hypothesis  that  explains  the  ligand/receptor-­‐‑independent  activation  of  GLI  in  the  
classical  subtype  of  LSCC  could  be  that  the  constitutively  active  PI3K/AKT  signaling  
caused  by  PIK3CA  amplification  or  PTEN  mutation  leads  to  GLI2  activation  in  addition  
to  the  canonical  PI3K-­‐‑AKT-­‐‑mTOR  signaling  cascade.  Although  GANT61  can  
significantly  decrease  GLI2  expression  in  NCI-­‐‑H520  cells,  we  notice  that  this  reduction  is  
greater  in  NCI-­‐‑H226  cell  line,  which  is  classified  as  a  PIK3CA-­‐‑wild-­‐‑type  line  with  low  
baseline  level  of  PI3K/AKT  signaling  (12).  It  is  likely  that  when  GANT61  lowers  the  
binding  capacity  of  GLI2  to  DNA  and  therefore  reduces  the  feedback  production  of  
GLI2,  endogenously  active  PI3K  signaling  is  able  to  compensate  the  partial  loss  of  GLI2  
by  suppressing  GLI2  degradation  and  even  upregulating  GLI2  expression.  Therefore,  we  
are  currently  studying  the  role  of  PI3K/AKT  signaling  in  regulation  of  GLI2  in  the  
classical  subtype  of  LSCC.  
7.2.2 Other potential GLI inhibitors 
An  important  question  in  the  clinical  setting  is  to  determine  which  patient  
should  receive  GLI  inhibitor  treatment.  In  the  TCGA  cohort,  we  observed  strong  
positive  correlation  between  PTCH1  and  GLI2  (Figure  36),  indicating  that  samples  with  
high  GLI2  tend  to  have  high  PTCH1,  and  vice  versa.  Therefore,  upregulation  of  either  
PTCH1  or  GLI2  can  be  used  to  determine  the  HH  signaling  activation.  Since  GLI1  may  
conduct  overlapping  functions  of  GLI2,  and  GANT61  can  inhibit  both  GLI1-­‐‑  and  GLI2-­‐‑  
mediated  transcription,  we  believe  that  the  expression  of  GLI1  should  also  be  tested  in  
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patient  specimens.  In  the  clinical  setting,  immunohistochemistry  staining  for  PTCH1,  
GLI2  and  GLI1  can  be  performed  in  patient  specimens  to  identify  HH-­‐‑GLI  active  patient  
tumors  as  demonstrated  by  previous  studies  shown  in  Figure  3  (41,  42),  which  show  that  
HH  signaling  components  are  overexpressed  in  LSCC,  but  absent  from  the  adjacent  non-­‐‑
neoplastic  lung  parenchyma.  Patients  with  hyperactive  HH-­‐‑GLI  signaling  should  be  
more  likely  to  respond  to  GLI  inhibition  therapy.  
Our  findings  highlight  the  need  for  agents  that  suppress  downstream  GLI  
effectors  with  high  efficacy  and  selectivity.  GANT61  is  a  relatively  new  member  in  the  
HH  inhibitor  family,  since  most  known  HH  pathway  antagonists  focus  on  the  
transmembrane  activator  SMO.  Other  readily  available  agents  that  inhibit  GLI2  are  rare.  
Arsenic  trioxide  (ATO),  which  is  FDA-­‐‑approved  treatment  for  acute  promyelocytic  
leukemia,  has  recently  been  described  as  a  potent  HH  inhibitor.  ATO  has  been  shown  to  
inhibit  HH  signaling  by  inhibiting  GLI2  ciliary  accumulation  and  promoting  its  
degradation  (63).  It  has  recently  been  shown  to  actively  inhibit  tumor  growth  in  known  
drug-­‐‑resistant  SMO  mutations  of  medulloblastoma  and  basal  cell  carcinoma  and  in  the  
context  of  GLI2  overexpression  (64).  Due  to  the  likelihood  that  compounds  that  block  
HH  pathway-­‐‑dependent  proliferation  in  one  cell  type  may  be  inactive  in  others,  the  
clinical  relevance  of  ATO  in  LSCC  treatment  is  currently  under  investigation.  
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Figure  36:  Scatterplot  of  GLI2  and  PTCH1  expression  in  the  TCGA  cohort 
Gene  expression  values  for  GLI2  and  PTCH1  from  the  TCGA  cohort  are  plotted  
and  colored  according  to  their  gene  expression  subtype.    The  expression  values  for  these  
two  genes  exhibit  a  strong  positive  association,  as  evidenced  by  the  high  positive  value  
of  the  Spearman  correlation  coefficient  (r2  =  0.61).  
  
7.2.3 Combined therapy of GLI inhibition, PI3K/AKT suppression, and 
cisplatin 
A  recently  emerging  idea  in  clinical  treatment  is  to  combine  several  anti-­‐‑tumor  
agents  that  specifically  target  different  signaling  pathways.  It  has  been  reported  that  GLI  
function  can  be  modulated  in  a  SMO-­‐‑independent  manner  by  PI3K/AKT  signaling  (30).  
Pharmacologic  inhibition  of  PI3K/AKT  signaling  reduced  tumor  growth  in  GDC-­‐‑0449-­‐‑
resistant  medulloblastoma  (50).  Several  inhibitors  of  the  PI3K  pathway  are  undergoing  
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clinical  evaluation.  PIK3CA  copy  number  gains  and  loss  of  PTEN  function  are  prevalent  
in  the  classical  subtype  of  LSCC,  where  the  activation  of  HH  signaling  was  observed.  
We  speculate  that  the  endogenously  active  PI3K/AKT  signaling  in  the  classical  subtype  
of  LSCC  can  positively  regulate  GLI  expression  and  activity.  This  coexistence  raises  the  
possibility  that  a  combined  therapy  of  GLI  inhibition  and  PI3K/AKT  suppression  may  be  
more  beneficial  than  a  monotherapy  to  enhance  efficiency  and  overcome  drug  resistance  
in  patients.  It  is  also  likely  that  treatment  of  GLI  inhibitors  and  PI3K/AKT  inhibitors  may  
increase  the  susceptibility  cancer  cells  to  conventional  chemotherapy.  Cisplatin,  which  
causes  cross-­‐‑linking  of  DNA  and  ultimately  triggers  apoptosis,  is  a  conventional  
platinum-­‐‑containing  chemotherapy  drug  for  treating  LSCC.  Despite  its  ability  to  induce  
DNA  damage,  cisplatin  has  a  number  of  side  effects  due  to  the  general  cytotoxicity.  The  
majority  of  cancer  patients  will  eventually  relapse  with  cisplatin-­‐‑resistant  disease  even  if  
initial  platinum  responsiveness  is  high.  Many  mechanisms  of  cisplatin  resistance  have  
been  proposed  including  changes  in  cellular  uptake  and  efflux  of  the  drug,  increased  
detoxification  of  the  drug,  inhibition  of  apoptosis  and  increased  DNA  repair  (65).  Solid  
tumors,  including  LSCC,  are  highly  heterogeneous.  The  actively  proliferating  cancer  
cells  are  usually  considered  to  have  aberrant  oncogenic  stimuli.  However,  the  stroma,  
which  creates  supporting  microenvironment,  is  likely  to  be  formed  by  normal  cells,  such  
as  blood  cells,  immune  cells  and  fibroblasts,  and  thus  may  be  less  sensitive  to  specific  
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pathway  inhibitors.  Therefore,  eliminating  these  stromal  cells  with  cisplatin  may  help  to  
enhance  the  targeting  efficacy  of  GLI  or  other  pathway  inhibitors.    
Taken  together,  there  are  two  aspects  we  would  like  to  study  for  potential  
clinical  application:  (1)  Combination  of  GLI  inhibitor  and  PI3K/AKT  inhibitor  in  LSCC  
cells  with  GLI  overexpression  and  hyperactive  PI3K/AKT  signaling.  (2)  Cisplatin  
treatment  plus  either  GLI  inhibitor,  or  PI3K/AKT  inhibitor,  or  both.  
7.2.4 Patient-derived xenograft models of LSCC 
Established  cancer  cell  lines  provide  convenience  for  in  vitro  studies,  particularly  
for  those  cancers  that  are  very  difficult  to  adapt  to  in  vitro  culture  system.  We  have  
observed  significant  efficacy  of  GLI  inhibitor  GANT61  in  representative  LSCC  cell  lines  
both  in  vitro  and  in  vivo.  However,  these  cells  may  have  accumulated  various  mutations  
rarely  seen  in  vivo  due  to  multiple  passages,  and  further  become  independent  of  or  less  
sensitive  to  a  signaling  pathway  essential  for  in  vivo  survival.  Moreover,  the  limited  
number  of  available  cell  lines  may  not  faithfully  represent  the  diversity  of  patient  
populations  and  biological  backgrounds.  These  shortcomings  of  using  cancer  cell  lines  
highlight  the  need  to  establish  an  in  vivo  system  that  can  directly  and  successfully  
propagate  the  primary  tumors  dissected  from  patients.    
LSCC  has  long  been  known  as  being  difficult  to  adapt  to  immunodeficient  mice  
with  a  substantially  low  tumor  take  rate.  In  collaboration  with  other  laboratories  and  
Duke  Core  Facility,  we  are  trying  to  collect  a  large  amount  of  LSCC  samples  and  
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develop  a  system  in  which  the  fresh  LSCC  tumor  is  minced  and  transplanted  
subcutaneously  into  Rag1-­‐‑/-­‐‑  mice.  A  few  number  of  primary  LSCC  may  be  successfully  
passaged.  Over  a  period  of  weeks,  tumors  start  to  grow  and  later  are  propagated  to  
more  new  Rag1-­‐‑/-­‐‑  mice.  Tumors  multiplied  in  mice  have  been  shown  to  better  maintain  
histological  features  and  the  gene  expression  pattern  at  both  message  and  protein  levels  
(66).  Furthermore,  patient-­‐‑derived  xenograft  tumors  maintain  at  least  some  aspects  of  
the  human  microenvironment  for  weeks  with  the  complete  substitution  with  murine  
stroma  occurring  only  after  2-­‐‑3  passages  in  mouse  (66),  which  therefore  represents  a  
more  realistic  model  for  preclinical  evaluation  on  drug  development.  This  system  will  
enable  us  to  conduct  in  vivo  drug  tests  across  a  broad  spectrum  of  original  patient  
samples.  
After  tumor  samples  are  harvested  in  the  operating  room,  a  small  portion  of  
tumor  tissues  will  be  immediately  processed  for  mRNA  and  protein  extraction,  while  
the  remaining  will  be  used  for  in  vivo  passage.  The  expression  level  of  GLI1  and  GLI2  
can  be  evaluated  by  Real-­‐‑time  PCR  or  Western  blot.  Section  slides  can  be  obtained  from  
pathology  department  after  histology  of  the  tumor  is  determined.  We,  therefore,  will  be  
able  to  identify  tumors  with  hyperactive  HH-­‐‑GLI  signaling  and  potentially  other  active  
oncogenic  pathways.  Based  on  our  genomic  analysis  and  previous  IHC  studies,  we  
anticipate  approximately  20%~30%  of  primary  LSCC  expressing  high  level  of  GLIs.  The  
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xenograft  tumors  of  these  GLI-­‐‑positive  samples  can  be  used  to  assess  the  therapeutic  
efficacy  of  GLI  inhibitor(s)  and/or  combined  therapies.  
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